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ABSTRACT 
 
Melissa H. Watt:  Understanding Patients’ Adherence to Antiretroviral Therapy: 
A Mixed-Methods Study in Arusha, Tanzania 
(Under the direction of Suzanne Maman, PhD) 
Background: Over one million HIV-positive people in Africa are taking antiretroviral 
therapy (ART), and this number is increasing.  Essential to the expansion of ART is ensuring 
patients’ optimal adherence to therapy. This study combined qualitative and quantitative 
methods to understand ART adherence at one site in Tanzania where patients received free 
medication.  The study measured ART adherence, identified factors associated with poor 
adherence, and explored how the social environment of patients’ lives supported adherence.  
A theoretical framework using the Social Cognitive Theory (SCT) and social support guided 
the study. 
Methods: Semi-structured interviews were conducted in Kiswahili with 36 adult ART 
patients and 6 health care providers. Patients described their experiences taking ART and 
managing adherence and providers described their experiences caring for patients.  A 
structured survey was conducted with 340 patients. Adherence was measured by self report, 
and patients were identified as having poor adherence if they took less than 95% of their pills 
during either the previous four days or one month. The survey measured correlates of 
adherence informed by the SCT, along with demographic and treatment variables. Factors 
associated with adherence were considered in a logistic regression model. 
Results: Only 5.9% (20/340) of patients reported poor adherence. Poor adherence was 
associated with: being young (19-30 years, vs. 31-40 years; OR=4.26, 95% CI 1.33-13.60); 
 iv
being old (over 50 years, vs. 31-40 years; OR=7.59, 95% CI 2.10-27.43); having lower 
perceived quality of patient-provider interaction (for each one-point decrease, OR=3.18, 
95%CI 1.29-7.83); and ever missing a clinic appointment (OR=3.75, 95% CI 1.29-10.89). 
Semi-structured interviews identified five factors to explain optimal adherence.  First, 
respondents experienced improved health on ART, which motivated adherence. Second, they 
linked pill-taking with routine activities. Third, they were motivated to stay healthy to meet 
family responsibilities. Fourth, material and emotional support from others facilitated 
adherence. Finally, respondents trusted health care providers’ instructions to adhere.  
Conclusions:  Adherence was high in this sample. Interventions to improve and sustain 
adherence should focus within the clinic to improve interactions between patients and 
providers and outside the clinic to bolster patients’ social support. Different strategies may be 
necessary according to patients’ ages. 
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I. INTRODUCTION 
Overview 
Approximately 33 million people around the world are living with HIV/AIDS, and 
almost 70% of those infected live in Sub-Saharan Africa, where the epidemic has been driven 
by heterosexual transmission (UNAIDS, 2007).  In 2007 alone, an estimated 1.6 million 
people died of AIDS-related illnesses in Africa, while a further 1.7 million people became 
infected with HIV, indicating that the epidemic in the region has not abated (UNAIDS, 
2007).  The impact of HIV/AIDS in Africa has been tremendous. Across the continent, life 
expectancy has fallen, in some cases as much as 20 years (World Health Organization, 2007).  
In addition to the social impact of losing loved ones in the prime of their lives, mortality 
among the most economically active members of society creates a spiral of poverty and a 
loss of human resources in sectors such as business, health and education. 
Antiretroviral therapy (ART) offers an opportunity to extend the lives of people living 
with HIV and to rejuvenate societies and economies that have been affected by the epidemic.  
Funds have been mobilized to provide free ART to people in the most affected countries, 
most notably through the US President’s Emergency Plan for AIDS Relief (PEPFAR) and 
the Global Fund for HIV/AIDS, TB and Malaria. The East African country of Tanzania, 
which has an adult HIV prevalence of 6.5% (UNAIDS et al., 2006), is a priority country for 
these funding sources and its national government has made a commitment to providing ART 
across the health care delivery system (Government of Tanzania, 2003). As of December 
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2006, 54,000 people were receiving ART in Tanzania, out of a total 420,000 in need (UN 
Office for the Coordination of Humanitarian Affairs, 2007).  
While access to ART is vital, it is equally important to ensure that people who are 
taking the medication achieve optimal adherence.  Taking at least 95% of prescribed pills is a 
primary determinant of successful clinical outcomes for patients on ART (Paterson et al., 
2000).  Poor adherence can result in viral resistance, progression of disease and death 
(Bangsberg et al., 2000). Experience with other long-term therapies has provided lessons that 
adherence is difficult to achieve and is influenced by factors at the individual, inter-personal 
and institutional levels (World Health Organization, 2003).  As ART services are expanded 
and sustained in Tanzania and throughout Africa, we must build a body of knowledge about 
patients’ experiences adhering to the medication.  This information will contribute to 
developing appropriate interventions and program models that can support adherence and 
therefore have the desired impact on improving patients’ health. 
Study aims 
This study took place at a faith-based clinic in Arusha, Tanzania, where 
approximately 700 patients were receiving free ART.  Based on a theoretical framework 
informed by the Social Cognitive Theory and the construct of social support, the study 
combined qualitative and quantitative methods to collect information about the factors that 
influenced patients’ adherence to ART.  The study was undertaken with four aims: 
1. To assess the level of adherence in a sample receiving free ART in Tanzania;  
2. To identify significant correlates of ART adherence;  
3. To explore how the social environment of patients’ lives supports ART adherence; 
and 
 3 
 
4. To assess the role of mediating and moderating factors in the relationship between 
social support and adherence.
  
II. LITERATURE REVIEW 
The Tanzanian context 
Tanzania is an East African country about one and a half times the size of Texas and 
home to 36.3 million people (Figure 2.1).  There are roughly 120 ethnic groups in Tanzania, 
none of which exceeds 10% of the country’s total population. The country is united by the 
national language of Kiswahili, which is taught in schools and spoken by the vast majority of 
Tanzanians as a first or second language. 
The city of Arusha is located in the north of 
the country and has a population of about 250,000 
(2002 census). Situated at a high elevation on the 
slopes of Mount Meru, the area has a temperate 
climate that makes it well suited for both subsistence 
and commercial agriculture, in particular coffee and 
flowers.  Being the gateway for visits to Tanzania’s 
renowned national safari parks and Mount 
Kilimanjaro, the city is an epicenter of Tanzania’s tourism industry. The area is traditionally 
inhabited by the Waarush, Wameru and Masaai ethnic groups, but the burgeoning economy 
of Arusha, combined with migration due to pressure on rural land in Northern Tanzania, 
makes Arusha an ethnic melting pot (Setel, 1999). The majority of Arusha residents are 
Christians and under a third are Muslims (Tanzanian National Bureau of Statistics et al., 
2005). 
Figure 2.1: Map of 
Tanzania
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The World Health Organization (WHO) classifies Tanzania as a low income country, 
due to its low gross domestic product (GDP) per capita and poor health indicators (Table 
2.1).  Development indicators in Tanzania have declined in the last decade. The Human 
Development Index, which incorporates three dimensions (living a long and healthy life; 
being educated; and having a decent standard of living) has fallen steadily since 1990 (United 
Nations Development Program, 2006). The life expectancy of Tanzanians was lower in 2005 
than in 1978 (World Health Organization, 2005b), due in part to the impact of HIV/AIDS on 
the country (Todd et al., 1997).  
The history of Tanzania, and therefore the history of its healthcare delivery system, 
has been greatly impacted by colonialism and global political and economic forces.  Prior to 
the late 19th century, Western medicine was unknown in the area, and people relied upon a 
diverse set of traditional healers, including both diviners and herbalists (Iliffe, 1998; 
Mandara, 1991).  The colonial era introduced Western medicine to Tanzania and brought the 
first missionary hospitals, established both to control communicable diseases and to win 
converts to Christianity (Iliffe, 1998; Mandara, 1991; Nieuwkerk et al., 2001).  Although 
Table 2.1: Development indicators for Tanzania, compared with the 
United States (United Nations Development Program, 2006) 
 Tanzania US 
GDP per capital income $674 $39,676 
Per capita government expenditure on health $29 $5,711 
Adult literacy rate (% ages > 15) 69.4% >99% 
Life expectancy at birth 45.9 77.5 
Total fertility rate 5.0 2.0 
Under 5 mortality rate (per 1000) 126 8 
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basic social services were expanded during the period of British rule, these services were 
concentrated in areas where colonial administrators and missionaries were based and 
benefited relatively few Tanzanians.   
When Tanzania gained independence in 1961, President Julius Nyerere vowed to 
forge a unique path of African socialism, which included nationalization of the country’s 
economic resources and resettlement of people into collective ujamaa villages, where 
communities owned communal land and shared in both the burden and fruits of labor 
(Nyerere, 1968).  It was in the context of this plan that Nyerere aimed to provide 
comprehensive preventive and curative health care to a largely rural population through 
village health posts.  By 1971, 90% of the country’s population was within walking distance 
of a rural health center (Barry et al., 1986).  In the mid-1980s, however, the country’s 
economic policies and the state of the global oil crisis sent Tanzania into a situation of 
economic disrepair.  In 1985, Nyerere resigned and Tanzania’s course was set for economic 
liberalization.  Health care expenditure fell; structural adjustment programs imposed by the 
World Bank introduced user fees that kept health services out of reach of many Tanzanians; 
and international donors began to fund a significant proportion of the national health care 
budget (Shiner, 2003).  Tanzania’s healthcare system is now challenged by poverty, debt, 
poor water and sanitation systems, inadequate and insufficient financing systems, and lack of 
both technological and human resources (World Health Organization, 2002b). As an 
indication of the limited capacity of the health care system, by 2002 there was only one 
doctor to every 50,000 people in the country (World Health Organization, 2007).    
Given the limitations of the government health infrastructure, church-based health 
facilities play a significant role in the provision of health care services in Tanzania. The 
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Lutheran church alone is responsible for 20 hospitals and 160 public health clinics, which 
they estimate to represent about 15% of all health services in the country (Evangelical 
Lutheran Church of Tanzania, 2007). There is some evidence that church-based health 
facilities provide better quality services than their government counterparts (Gilson et al., 
1995) and that communities have a more favorable impression of church-based facilities 
(Gilson et al., 1994).   
 While formal health facilities may be the most recognizable health infrastructure to 
the outside eye, these facilities co-exist with a set of traditional health-seeking behaviors.  
Traditional healers (waganga) are a part of the healing system across tribal groups, offering 
treatment for a multitude of health ailments (Kayombo et al., 2007; Rekdal, 1999).  People 
may seek treatment from traditional healers either serially or concurrently with biomedical 
care in health facilities.  In an ethnographic study on the treatment of sexually transmitted 
infections (STIs) in a rural area of Western Tanzania, researchers found that health-seeking 
behavior was “pluralistic and opportunistic” (Plummer et al., 2006).  People in this area often 
began treatment for suspected STIs with home remedies before seeking the services of a 
traditional healer. Only if those failed did they attend formal health facilities.   
 An important distinction that has often been made between traditional healing 
practice and Western biomedical care is that traditional practice engages the patient’s larger 
social network, while Western care has taken a very individualistic approach (Turshen, 1984, 
p. 148).  The focus of traditional healing practice on the patient’s social network is consistent 
with what has been described as a “therapy management group,” where a set of family 
members and friends mobilize around a patient with the purpose of “sifting information, 
lending moral support, making decisions and arranging details of the therapeutic process 
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(Janzen et al., 1978, p. 4).”  This concept emphasizes the importance of formal health care 
facilities to make space for and engage the patient’s social support system in the process of 
care.  
The impact of HIV/AIDS in Tanzania  
The first cases of AIDS in Tanzania were recorded in 1983, and since that time the 
impact of the virus has been felt increasingly around the country. In 2005 alone, 
approximately 140,000 people died of AIDS in Tanzania, and there are currently 1.3 million 
adults living with HIV in the country, of whom about 55% are women. In addition, 
approximately 110,000 children are living with HIV and over one million Tanzanian children 
have been orphaned by AIDS (UNAIDS et al., 2006). 
At the end of 2006, UNAIDS estimated that approximately 6.5% of the adult 
population were infected with HIV (range: 5.8 – 7.2%) (UNAIDS et al., 2006). The UNAIDS 
estimate is derived from national-level data, which is based primarily on surveillance data of 
women attending antenatal clinic in sentinel sites.  There is evidence that the HIV prevalence 
in Tanzania has steadied or declined over the last several years, although this appears to be 
more a factor of the rise in HIV-related deaths than a decline in new infections (Somi et al., 
2006; Urassa et al., 2006). 
The Tanzanian HIV/AIDS Indicator Survey is the first population-based survey of 
HIV/AIDS to cover all 21 regions in mainland Tanzania (Tanzanian Commission for AIDS 
et al., 2005).  The representative probability sample included 6,900 households, including a 
total of 12,522 individual household members (55% female) ages 15-49. All adult household 
members completed separate questionnaires and provided blood samples for anonymous HIV 
testing, which were linked with their responses. The total HIV prevalence of the population 
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was 7.0%, with variations by region, sex and age. The highest prevalence rates were found in 
Mbeya (13.5%) and Iringa (13.4%) regions, both located on the southern border of Tanzania, 
and in Dar es Salaam (10.9%), the capital city. Respondents in the Arusha region had an HIV 
prevalence of 5.3%. The HIV prevalence by age group and sex indicate that women become 
infected at younger ages than men (Figure 2.2).  HIV prevalence was highest among women 
in the age group 30-34 and among men in the age group 40-44. This trend has been observed 
in other settings and is attributed to 
women’s biological vulnerability to HIV 
at younger ages, as well as a 
tendency for women to be in 
relationships with older men 
(Glynn et al., 2001; Gregson 
et al., 2002; Pettifor et al., 
2005). 
Little systematic 
research has been done on the 
social and economic impacts of the HIV epidemic in Tanzania. The Tanzanian government 
indicates that HIV/AIDS is draining the productive work force, with a negative macro and 
micro impact on the economy. They predict that Tanzania’s GDP will be 15-20% lower in 
2010 than it would have been without the AIDS pandemic. The provision of social services 
will be particularly impacted by increasing mortality. The Minister of Education has 
estimated that 114 teachers die of AIDS each month, presenting a gap in experienced 
personnel where there is often no replacement (Government of Tanzania, 2003). A similar 
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Figure 2.2: Percentage of Tanzania’s population 
infected with HIV, by age group and sex (Tanzanian 
Commission for AIDS et al., 2005) 
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impact is likely to be felt in the health sector, as nurses and doctors become infected with 
HIV. 
There is evidence that HIV mortality is shifting the demographic distribution of the 
country. As early as 1992, a study in Mwanza Region of Tanzania found that with a 
relatively low prevalence of 4%, HIV had increased overall adult mortality in that region by 
more than 50% and more than doubled the number of deaths in the 20-29 year old age range 
(Todd et al., 1997).  As a result of the long duration of illness and the plethora of AIDS-
related infections, the epidemic is putting a great strain on already stretched hospital 
resources. In a large hospital in Moshi, in Northern Tanzania, a single-day, point-prevalence 
survey in 2001 found that 21% of all hospital inpatients were infected with HIV (Ole-
Nguyaine et al., 2004). A methodologically similar study in urban Bukoba, in North-West 
Tanzania, found an HIV prevalence rate among admitted patients of 33%, with a prevalence 
of 53% among 25-34 year old patients (Kwesigabo et al., 1999). A study in rural North-West 
Tanzania found that in half of all HIV-related deaths, the person had never been admitted to 
the hospital, indicating a potentially large unmet need for HIV-related medical care (Ngalula 
et al., 2002).  
The Tanzanian Government has acknowledged the broad-reaching impact of the 
HIV/AIDS epidemic and the need to provide a coordinated response.  With technical 
assistance from the United States Agency for International Development (USAID) and the 
World Bank, the Tanzanian Commission for AIDS (TACAIDS) was launched in 2001 to 
coordinate the activities of all levels and sectors of government and to engage with 
multilateral donors in responding to the epidemic.  The charge is guided by the National 
Multi-sectoral Strategic Framework on HIV/AIDS 2003-2007 and the National HIV/AIDS 
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Policy, both of which emphasize a multi-pronged approach of prevention, care and treatment 
involving multiple sectors of government and civil society. 
Antiretroviral therapy as an opportunity to mitigate the impact of HIV 
Antiretroviral therapy (ART) is one piece of a comprehensive response to mitigate the 
impact of the HIV/AIDS epidemic. ART, first introduced in the United States as combination 
therapy in 1996, has been an extraordinary life-prolonging tool for people living with HIV.  
ART regimens combine multiple drugs to reduce the amount of virus in the blood and 
increase the production of CD4+ T-cells, which allow the body to ward off infections.  Just a 
few years after ART became widely available in the United States, studies reported 60% to 
80% reductions in new AIDS-related illnesses, hospitalizations and deaths (Jensen-Fangel et 
al., 2004; Kaplan et al., 2000; Kleeberger et al., 2004; Paul et al., 1999). In Rio de Janeiro, 
Brazil, introduction of free ART reduced the number of AIDS deaths by 47.5% during the 
period 1995 to 2003 (Saraceni et al., 2005).  Successful ART can change HIV from an illness 
that was almost always a death sentence into a chronic, manageable condition.  
While ART was previously available only in resource-rich countries, generic 
production of ART has reduced the annual price of first-line regimens from approximately 
$10,000 in 2000 to $150 in June 2005, making the goal of universal access to ART more 
feasible (Medecins sans Frontieres, 2005).  ART regimens have also become more simple to 
take and administer.  Whereas initial formulations required patients to take several pills at 
multiple times of day, the newest regimens on the market require just one pill, once a day 
(Killingley et al., 2007).  At the same time as there have been changes in the affordability and 
simplicity of ART, there has been a dedication of political will and resources to make ART 
available in developing countries, seen in large part because of the activism of HIV-positive 
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individuals and organizations (Behrman, 2004). The call to expand ART services has 
increasingly been framed as an issue of human rights (Behforouz et al., 2004; Farmer, 2005; 
Galvao, 2005; Solomon, 2005).  A rights-based approach is used to hold the international 
community accountable to responding to people living with HIV/AIDS, and to ensure access 
to affordable treatment for the world’s poorest and most marginalized communities 
(Roseman et al., 2004).  
In 2003, the World Health Organization (WHO) embarked upon an initiative to 
provide ART to 3 million people in developing countries by 2005. The strategy was 
underpinned by principles of urgency, equity and sustainability, and was embedded in a 
human rights framework. In launching what was called the ‘3 x 5’ initiative, the WHO set the 
following goal: 
The goal of the Initiative is for WHO and its partners to make the greatest 
possible contribution to prolonging the survival and restoring the quality of 
life of individuals with HIV/AIDS, advancing toward the ultimate goal of 
universal access to antiretroviral therapy for those in need of care, as a human 
right and within the context of a comprehensive response to HIV/AIDS. By 
the end of 2005, 3 million eligible people in developing countries who need 
antiretroviral therapy will be receiving effective antiretroviral therapy. 
(WHOQOL Group, 1998) 
 
It is now clear that the global community has made progress in the provision of ART 
but has missed the mark on meeting its ambitious target of three million on therapy. In June 
2006, the WHO estimated that 1.6 million of the 6.5 million people who were in need of 
ART were receiving it (World Health Organization et al., 2006) (Table 2.2).  The scale up of 
ART has been most dramatic in sub-Saharan Africa, increasing from 100,000 on ART at the 
end of 2003 to over one million on ART in mid-2006. 
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Table 2.2: ART coverage in low and middle income countries, June 2006 (World Health Organization et al., 
2006) 
Region Number receiving  ART Number needing ART Coverage 
Sub-Saharan Africa 1,040,000 4,600,000 23% 
Latin America & Caribbean 345,000 460,000 75% 
East, South & S.E. Asia 235,000 1,440,000 16% 
Europe & Central Asia 24,000 190,000 13% 
N. Africa & Middle East 4,000 75,000 5% 
TOTAL 1,650,000 6,800,000 24% 
 
While these numbers present some progress on the scale-up of ART in developing 
countries, they fail to tell the full story.  First, it is unclear how accurate the numbers are, 
given that they are based on generally weak routine health information systems.  Further, the 
numbers beg additional questions, such as: How many people have survived once beginning 
ART?  What has been the dropout rate of people starting ART?  How many people have 
developed drug resistance and had to switch regimens?    
In the next era of ART scale-up, an estimated US$27 billion is available or has been 
pledged from all sources to expand ART services in 2005-2007, but WHO estimates that an 
additional $18 billion is needed (World Health Organization, 2005a). Funds have been 
mobilized through the Global Fund to Fight AIDS, Tuberculosis and Malaria, PEPFAR, the 
World Bank, and other bi-lateral and multi-lateral initiatives. The challenge will be to ensure 
that the funds are used effectively to not only make drugs available, but also to build the 
physical and social infrastructure that will support patients to effectively take medications for 
the rest of their lives.   
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Antiretroviral therapy in Tanzania  
Tanzania is committed to expanding ART access to all the people who are in need, 
and has received assistance from international donors to do so.  The Tanzanian HIV/AIDS 
Care and Treatment Plan 2003-2008 guides the national scale-up of ART (Government of 
Tanzania, 2003). In this document, the Government set out four inter-related goals for 
treatment:  
1. To provide quality, continuing care to as many HIV-positive people as possible 
2. To strengthen the healthcare structure through expansion of healthcare personnel, 
facilities, and training in the care and treatment of HIV/AIDS 
3. To foster communication efforts to increase public understanding of care and treatment 
alternatives and reduce HIV-related stigma 
4. To strengthen social support for care and treatment of people living with HIV/AIDS, 
including home-based care, 
support groups and treatment 
partners 
The national plan 
established specific target goals 
for the number of people on ART 
from 2004-2008 (Government of 
Tanzania, 2003). As of December 
2006, 54,000 people were 
receiving ART across the 
country, out of 420,000 in need 
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Figure 2.3: Number receiving ART in Tanzania as of December 
2006, compared with Government’s goals (Government of 
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Affairs, 2007) 
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(UN Office for the Coordination of 
Humanitarian Affairs, 2007).  This 
number falls far short of the 
government’s goal of 151,000 on 
treatment by the end of 2006 (Figure 
2.3). The reasons for this short-
coming have not been identified, but 
potential challenges that were 
indicated in the national plan and that 
have been observed in other countries’ experiences providing access to ART include: slow 
drug procurement, insufficient laboratory capacities, poor accessibility of voluntary 
counseling and testing services, lack of trained personnel, poor outreach to people in need of 
ART, and community-level stigma (Kober et al., 2004; McCoy et al., 2005). Even though the 
number of people on ART in Tanzania falls short of the government’s stated targets, there 
has nevertheless been significant progress over the preceding two years (Figure 2.4).   
The national provision of ART is coordinated by the Tanzanian Department of 
Health.  Sites that deliver ART are identified as care and treatment centers (CTC sites).  As 
of December 2006, there were 200 CTC sites across the country, representing a mix of 
government, faith-based and charity-run health facilities (UN Office for the Coordination of 
Humanitarian Affairs, 2007).  While provision of ART is disproportionately located in urban 
sites, there is increased commitment to making treatment available in rural areas. 
Financial resources are available to Tanzania to support its expansion of ART 
services. The Clinton Foundation, which provides technical and financial assistance for 
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Figure 2.4: Number receiving ART in Tanzania, as 
reported in 2004, 2005 and 2006 (UN Office for the 
Coordination of Humanitarian Affairs, 2007) 
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HIV/AIDS treatment in Tanzania, estimates that Tanzania will spend $500 million in the next 
five years to provide ART to people living with HIV/AIDS (Clinton Foundation, 2006).  This 
includes funds from the United States’ PEPFAR program, which has committed $15 billion 
over five years to address HIV/AIDS in nine of the most affected countries including 
Tanzania, and the Global Fund to Fight AIDS, Tuberculosis and Malaria, which approved 
$216 million for Tanzania during the first four rounds of funding proposals (Global Fund to 
Fight AIDS TB and Malaria, 2005).  However, even this fairly large infusion of funds may 
be insufficient to not only purchase the necessary medications, but also to build the 
supporting healthcare delivery system in a country where the per capita government 
expenditure on all health care costs is just $29 (United Nations Development Program, 
2006). 
Importance of adherence to antiretroviral therapy 
One of the greatest challenges of rapid scale-up of ART services is to ensure patients’ 
adherence to medications.  
Several studies have 
demonstrated that adherence 
to ART is the strongest 
predictor of progression to 
AIDS and death (Bangsberg 
et al., 2001; Garcia de Olalla 
et al., 2002; E. Wood et al., 
2003b; E. Wood et al., 
2002).  The most commonly 
21.7
54.6
66.7 71.4
82.1
0
10
20
30
40
50
60
70
80
90
%
 w
ith
 d
et
ec
ta
bl
e 
vi
ra
l 
lo
ad
95-
100%
90-
94.9%
80-
89.9%
70-
79.9%
<70%
% of pills taken
Figure 2.5: Percentage of patients with virologic failure 
and adherence to ART (Paterson et al., 2000) 
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cited evidence of what constitutes ‘good’ adherence is a study by Paterson, Swindells et al 
(2000).  Measuring both adherence and clinical outcomes in 99 ART patients in a U.S. 
hospital, the authors demonstrated that a threshold of 95% adherence was associated with 
less risk of virologic failure (defined as an HIV RNA level greater than 400 copies/ML) 
(Figure 2.5). In addition, at least 95% adherence was associated with an increases in CD4 
lymphocyte count and lower hospitalization rates (Paterson et al., 2000).  Using this study 
and subsequent evidence that greater than 95% adherence is associated with better clinical 
outcomes, 95% adherence is most often used as the threshold between poor and good 
adherence (Ammassari et al., 2001; Cederfjall et al., 2002).  
While there appears to be a dose-response relationship between adherence and viral 
load, the relationship between adherence and the development of drug-resistant mutations of 
the virus has shown a different pattern.  Several recent studies have demonstrated a skewed 
bell-shaped relationship between adherence and detection of drug-resistant mutations, in 
which high but imperfect adherence (80% - 90% adherence) was associated with the greatest 
risk of drug-resistant mutations (Bangsberg et al., 2004; Harrigan et al., 2005; M. S. King et 
al., 2005).  These results do not negate previous data suggesting a dose-response relationship 
between adherence and disease progression and mortality (Bangsberg et al., 2001; Garcia de 
Olalla et al., 2002; E. Wood et al., 2003a; E. Wood et al., 2002), but they do suggest a 
renewed challenge to ensure that patients’ adherence is nearly perfect in order to guard 
against drug failure and poor health outcomes.  
Suboptimal adherence to ART regimens has implications at both the individual and 
population levels. As noted above, at the individual level poor adherence is associated with 
progression to AIDS, increased risk of mortality and development of drug-resistant mutations 
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of the virus.  The drug-resistant mutations of the virus may render easier to administer first-
line drugs ineffective for patients, requiring second-line drugs that are more complicated, 
more costly and carry greater side effects. This is particularly problematic in developing 
country settings, where second-line drugs are hard to come by and viral load testing is rarely 
available (Cohen, 2007).  At the population level, drug-resistant viral strains can be 
transmitted through new infections, and implications for treatment may be similar to the 
spread of multi-drug resistant strains of tuberculosis (Alvarez et al., 2004).  Small cohorts of 
patients in African populations have shown the emergence of drug-resistant strains of HIV in 
both treatment-naïve and ART-experienced patients (Laurent et al., 2005; Richard et al., 
2004; Toni et al., 2003; Weidle et al., 2001; Weidle et al., 2002).  Some suggest that unless 
the expansion of ART services is coupled with health and community systems that can 
support patients to adhere, it is possible that the rapid scale-up of ART services may do more 
harm than good (Gill et al., 2005; Harries et al., 2001). 
Review of studies on ART adherence 
 Adherence is a challenge across chronic therapies. A review by the World Health 
Organization found that medication adherence across long-term therapies in developed 
countries is only in the range of 50% (World Health Organization, 2003). The authors of the 
report speculated that adherence may be even more problematic in developing countries, 
where there are additional challenges of access and supply.  The findings of adherence to 
ART in Africa, however, have been fairly encouraging, holding at bay what some have 
termed as the potential of “antiretroviral anarchy” (Harries et al., 2001). A meta-analysis 
comparing ART adherence in North American settings and African settings found that 
patients in Africa had better adherence than their North American counterparts, with a pooled 
 19 
 
estimate of 77% of participants in African studies achieving adequate adherence, compared 
with just 55% in North American studies (Mills, Nachega, Buchan et al., 2006). In both 
settings, however, the measures of adherence were not consistent across the studies.  
A review of studies in African settings that measured adherence and assessed factors 
associated with adherence identified seven studies (Table 2.3). Six of the seven studies 
measured adherence by patients’ self-report, but these differed in the referent time interval (3 
days, one week, one month, one year). One study measured adherence based on pharmacy 
pill count when patients returned for their monthly refill. All studies but one reported 
adherence as a dichotomous measure with patients compared to a standard of good adherence 
(most generally taking >95% of one’s pills).  
 
Table 2.3: Adherence measures and proportion of sample with poor adherence in studies in African 
countries 
 
 
Reference 
 
 
Setting 
 
 
Adherence measure 
% of 
sample 
with poor 
adherence 
 
1. Byakika-Tusiime et 
al., 2005 
Uganda Self report: Proportion of doses taken 
in the past 3 days 
Adherence dichotomized at + 95% 
  
32% 
2. Diabate et al., 2007 Ivory Coast Self report: Proportion of doses taken 
in the past 3 days 
Adherence dichotomized at + 95% 
 
25.7% 
3. Eholie et al., 2007 Ivory Coast Self report: Proportion of doses taken 
in the past 7 days 
Adherence dichotomized at + 95% 
 
76% 
4. Laniece et al., 2003 Senegal Self report: Mean of pills taken over 
last 30 days 
Mean adherence: 91% 
 
 
n/a 
5. Nachega et al., 2004 South Africa Self report: Proportion of doses taken 
in the past month 
Adherence dichotomized at + 95% 
12% 
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6. Orrell et al., 2003 South Africa Monthly clinic pill-count: As a 
continuous measure, the median 
adherence for the cohort was 93.5% 
(mean, 87.2%). For analysis, 
adherence was dichotomized at + 
95% 
  
54% 
7. Weiser et al., 2003 Botswana Self report: Proportion of doses taken 
in the past year 
Adherence dichotomized at + 95% 
46% 
 
 The measurement of adherence has been a consistent challenge.  As Wu and 
colleagues state: “There is only vague consensus on what it is we are trying to measure, and 
there is a diversity of practice on when, how and what to measure” (Wu et al., 2002).  
Measures of adherence can be divided into two categories: subjective (patient self-report) and 
objective (pill count or technological devices) measures. Validation of adherence measures is 
generally done by looking at the correlation of the measures with patients’ HIV viral load 
(Montessori et al., 2004).  
Self-reported measures of adherence are often chosen because they are easier, less 
costly and more feasible to administer than other more objective measures of adherence.  
Most self-report measures involve asking patients to recall the proportion of times that they 
correctly took their medications over the past 3-, 4-, 7-, or 28-day period (Reynolds, 2004).  
Self-reported measures have shown to consistently over-estimate adherence when compared 
with more objective measurements such as pill counts or electronic pill caps (Arnsten et al., 
2001; M. A. Chesney, Ickovics et al., 2000; Liu et al., 2001; G. J. Wagner et al., 2000).  For 
example, in a six month observational study, mean one-week estimates of adherence by self-
report were 78%, but mean one-week estimates by electronic pill cap were 53% (Arnsten et 
al., 2001).  Both of these measures were correlated with viral load, as has been seen in other 
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studies (Arnsten et al., 2001; Duong et al., 2001; Fairley et al., 2005; Fletcher et al., 2005; 
Liu et al., 2001).  Over-reporting adherence is often attributed to social desirability 
(Reynolds, 2004), but a small pilot study found that difficulties in recall played a more 
important role in accurate self-reporting than social desirability (G. Wagner et al., 2004).  No 
social or cognitive variables have been identified to differentiate between those who 
accurately report adherence and those who do not accurately report adherence (Kimmerling 
et al., 2003).  Despite the short-comings of self-reported measures of adherence, self report is 
nevertheless considered a robust and appropriate way to assess adherence (Simoni et al., 
2006).  
Multiple studies have considered the correlates of adherence in industrialized country 
settings, and several review articles have synthesized the findings (Ammassari, Trotta et al., 
2002; M. Chesney, 2003; M. A. Chesney, 2000; Fogarty et al., 2002; Ickovics et al., 2002a, , 
2002b; Mills, Nachega, Bangsberg et al., 2006; Reynolds, 2004; Tsasis, 2001). There is little 
consistency across studies of the predictor variables that are measured and hence those that 
are found to be associated with adherence. One review paper identified only a few factors 
have been consistently associated with poor adherence: side effects, psychological distress, 
lack of social or family support, complexity of the HAART regimen, low patient self-
efficacy, and inconvenience of treatment (Ammassari, Trotta et al., 2002).  In addition, 
supportive patient-provider relationships have been shown to be associated with better 
adherence (M. Chesney, 2003).  
In order to synthesize findings on ART adherence in sub-Saharan countries, a 
systematic review of the literature in the Medline database was conducted using the key 
words: HIV, AIDS, adherence, compliance, ART, ARV, HAART.  Studies were identified 
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that met the following criteria: (1) considered adult adherence to ART as the dependent 
variable of interest; (2) used patient-level data to examine the correlates or predictors of 
adherence; and (3) were conducted in a sub-Saharan African country. Seven studies met 
these criteria, representing Uganda, the Ivory Coast, Senegal, South Africa and Botswana 
(Table 2.4).  The sample sizes ranged from 66 to 591, with a mean sample size of 260. In six 
of the studies, at least some of the patients had to purchase ART.  Four of the studies used a 
cross-sectional study design, while three used a prospective study design. All the studies 
involved face-to-face interviews, where the interviewer asked questions about adherence 
behaviors and the predictor variables.  
 
Table 2.4: Characteristics of studies that looked at factors associated with adherence to ART in 
African countries 
 
Reference Setting Sample Study design 
1. Byakika-Tusiime 
et al., 2005 
Uganda 
3 urban clinics  
 
304  
(all purchasing ART) 
Cross-sectional 
structured interviews 
 
2. Diabate et al., 
2007 
Ivory Coast 
1 urban clinic 
591 
(unclear whether 
patients purchased 
ART) 
 
Prospective: 
structured interviews 
3. Eholie et al., 2007 Ivory Coast 
3 urban clinics 
 
308 
(all purchasing ART) 
Cross-sectional 
structured interviews 
4. Laniece et al., 
2003 
Senegal 
1 urban clinic 
158 
(1/2 purchasing ART; 
1/2 receiving free 
ART ) 
 
Prospective: 
structured interviews 
5. Nachega et al., 
2004 
South Africa 
1 urban clinic 
 
 
66  
(1/3 purchasing ART; 
2/3 receiving ART 
through clinical 
trials) 
 
 
 
 
Cross-sectional 
structured interviews 
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6. Orrell et al., 2003 South Africa 
1 urban clinic 
 
289 
(all receiving free 
ART through a 
clinical trial) 
Prospective: 
structured interviews 
followed by monthly 
pill counts over 48 
weeks 
 
7. Weiser et al., 
2003 
Botswana 
3 urban private clinics 
109 
(all purchasing ART) 
Cross-sectional 
structured interviews 
 
Similar to studies in industrialized country settings, there was little consistency across 
these studies of the factors that were measured as potential predictors and those that were 
found to be significantly associated with adherence. The factors that were studied fall into six 
broad categories. (A chart including the factors that were measured in each of the studies and 
their statistical significance in multivariate analysis is included as Appendix One). 
• Demographic factors:  All studies included measures of demographic 
variables. Age, gender, education and socio-economic status were measured in the majority 
of studies. Two studies found that younger age was associated with poor adherence in 
multivariate models (Nemes et al., 2004; Orrell et al., 2001). Gender was not associated with 
adherence in any of the studies. Two studies found that higher levels of education were 
associated with poor adherence (Eholie et al., 2007; Weiser et al., 2003). Only one study 
found an association between low socio-economic status (SES) and poor adherence, although 
SES was measured differently in each of the studies. Where SES was a significant predictor, 
it was measured as monthly income less than US$50 (Byakika-Tusiime et al., 2005). It is 
important that where SES was a predictor of adherence all patients were purchasing ART. 
One study found that poor adherence was associated with being single, which may be an 
indication of low social support (Byakika-Tusiime et al., 2005).  
• Psychological factors:  Four studies included measures of psychological 
variables. The only psychological variable that was significant in multivariate regression was 
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HIV optimism, measured by a single question of whether patients were less worried about 
their HIV infection now that treatment had improved (Diabate et al., 2007). 
• Social factors:  Four studies included measures of social influences. One study 
found that fear of stigmatization by a partner was significantly associated with worse 
adherence (Nachega et al., 2004), but this association was not explored in a multivariate 
model.  Low social support was found to be a significant predictor of poor adherence in a 
study in Ivory Coast (Diabate et al., 2007), but was not significant in a study in Uganda 
(Byakika-Tusiime et al., 2005). Disclosure of HIV status was measured in a Botswana study 
and showed a trend of non-disclosure being associated with poorer adherence.  In their study, 
69% of patients did not disclose their HIV status to their families, and 94% did not disclose 
to people in their community. In an open-ended question of why patients missed ART doses, 
15% reported missing doses due to stigma (Weiser et al., 2003).  
• Institutional factors:  Four studies included institutional variables in their 
measures, including access to the clinic, costs of medication and availability of counseling. 
Only cost of medication was a significant barrier to poor adherence. In a study in Botswana, 
patients who reported cost of ART as a problem were more likely to have poor adherence 
(Weiser et al., 2003), and in a study in Senegal, the reduction of the price of ART resulted in 
better adherence (Laniece et al., 2003). 
• Factors related to ART treatment:  All studies considered the relationship 
between adherence and treatment-related variables. An increasing number of pills and/or 
doses per day was significantly associated with poor adherence in two studies in multivariate 
analysis (Diabate et al., 2007; Orrell et al., 2003).  In Senegal, patients taking regimens 
containing efavirenz had better adherence than patients taking regimens containing indinavir 
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(Laniece et al., 2003). The two studies that considered reported side effects did not find an 
association between side effects and adherence. There was also no association between time 
on ART and adherence in the four studies that measured this.  
While the studies that have been conducted shed some insight on possible 
determinants of ART adherence in African settings, they also point to inconsistencies in both 
the predictor variables that were measured and those that were found to be significantly 
associated with adherence. The studies focused overwhelmingly on individual and clinical 
factors, with only scant attention to interpersonal or community dynamics that may influence 
adherence. None of the reviewed studies included a theoretical model, and none looked at 
mediated or moderated relationships of adherence, which would help to explain not only 
what factors are associated with adherence, but how those factors influence adherence. 
Further, most of the studies used a cross-sectional study design, which is limited in both its 
ability to show causation, as well as its ability to detect temporal differences in adherence 
rates (Spire et al., 2002).  Very few studies on ART adherence in Africa have used qualitative 
methods, which would provide a more nuanced view of patients’ experiences negotiating 
adherence (Crane et al., 2006; Hardon et al., 2007; Nachega et al., 2006).
  
III. THEORETICAL FRAMEWORK 
 Various theories have been used to explain variations in ART adherence and 
to inform adherence interventions. These include the trans-theoretical model (Rogers et al., 
2001), the social cognitive theory (Fourney et al., 2003; Safren et al., 2001; Smith et al., 
2003; Tuldra et al., 2000), the social action theory (Remien et al., 2003), the health belief 
model (Fourney et al., 2003; McPherson-Baker et al., 2000), the theory of group-mediated 
social control (Broadhead et al., 2002), the self-regulation theory (Reynolds, 2003), and the 
information, motivation and behavior skills model (Fisher et al., 2003; Harman et al., 2005).  
The use of theory in this field is young and disjointed.  Amico and colleagues (2005) 
succinctly assess the limited use of theory in ART adherence research, and the importance of 
developing multivariate, theory-based models: 
Thus far, exploration of the determinants of ART adherence has been 
dominated by the ‘single-variable,’ predictive approach. While this work has 
provided valuable information regarding the associations between individual 
variables and adherence, it does not present a sufficiently complex view of the 
factors associated with ART adherence. Multivariate, theory-based models are 
only now emerging, and the evaluation of such models is critical in the 
development of effective interventions (Harman et al., 2005). 
 
One of the problems with how theory has been applied in the field of ART adherence 
is that it has limited its lens to the individual level, failing to consider how the social context 
and interpersonal relationships influence patients’ adherence. Studies of the correlates of 
adherence to ART have consistently found that adherence is influenced by variables at 
multiple levels of the social-ecological framework, including factors inherent to the 
individual, the individual’s relationships, and characteristics of the physical and social 
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environment (Ammassari, Antinori et al., 2002; M. Chesney, 2003; Fogarty et al., 2002; 
Ickovics et al., 2002b; Mills, Nachega, Bangsberg et al., 2006; Sankar et al., 2006; Vervoort 
et al., 2007). 
This dissertation study integrated social support with constructs from social cognitive 
theory to explore the determinants of ART adherence. Social support is defined as assistance 
that is given through formal or informal relationships with the intention of being helpful for 
the beneficiary (Heaney et al., 2002), and has been categorized into four broad forms of 
supportive behaviors (emotional, instrumental, informational and appraisal) (Ferguson et al., 
2002).  Social cognitive theory is a behavioral theory that integrates intrapersonal and 
interpersonal levels of the social ecological framework and situates them together in a 
dynamic environment. The organizing concept of SCT is reciprocal determinism, which 
asserts continual interaction between the behavior, the person, and the physical and social 
environment (Baranowski et al., 2002).  Albert Bandura, who has been refining the SCT 
since the 1970s, has identified five core constructs of SCT (Bandura, 1977):  
1. Knowledge of health risks and benefits of a behavior 
2. Self-efficacy to perform a behavior 
3. Outcome expectations of a behavior 
4. Goal setting and strategies to attain a goal of health behavior 
5. Perceived facilitators and obstacles to performing a behavior 
Drawing upon these theories, and considering empirical evidence of the determinants 
of ART adherence, I proposed a conceptual model to explain variations in patients’ 
adherence to ART (Figure 3.6). This is a broad heuristic that asserts that adherence to ART is 
influenced by factors at multiple levels of the social-ecological framework.  Below, I 
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describe the ten predicted determinants, their theoretical underpinnings, and evidence of 
associations with ART adherence. 
Individual level 
 Psychological and behavioral factors at the individual level are important for 
explaining ART adherence. All of the individual-level determinants are informed by the 
social cognitive theory. 
1. Perceived self-efficacy to adhere to ART 
Self-efficacy is defined as “the confidence a person feels about performing a 
particular activity, including confidence in overcoming the barriers to performing that 
behavior” (Baranowski et al., 2002). Bandura (2004) asserted that self-efficacy is perhaps the 
strongest determinant in influencing whether a person will undertake a particular behavior. 
For people who have never taken chronic medication before, the idea of taking pills every 
day, for the rest of one’s life, can be daunting.  This is particularly the case in the face of 
disrupting circumstances, such as experiencing side effects, traveling, or trying to hide one’s 
HIV status. Adherence requires confidence that one can take the pills every day, even in the 
face of difficult circumstances. Self-efficacy has been associated with adherence in several 
studies (Catz et al., 2000; M. A. Chesney, Ickovics et al., 2000; Gifford et al., 2000; Godin et 
al., 2005; Wilson et al., 2004), including one study in a developing country setting (Pinheiro 
et al., 2002). 
2. Skills or strategies applied for taking ART 
The SCT identifies goal-setting and specific strategies to achieve goals as important 
for achieving behavior change (Bandura, 1977). Qualitative studies have identified the use of 
skills and strategies to ensure adherence including: pillboxes, alarm devices, carrying pills in 
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a bag, and associating pill taking with other daily activities (Adam et al., 2003; C. Golin, 
Isasi et al., 2002; Kumarasamy et al., 2005; Ryan et al., 2003).  In a study in Costa Rica, 
people who set out their pills on a daily basis had better adherence than people who did not 
use this strategy (Stout et al., 2004).  In a prospective study in the United States, patients who 
used some adherence aids had significantly better adherence than patients who used no 
adherence aids (C. E. Golin, Liu et al., 2002b).  
3. Knowledge of ART  
The SCT views knowledge of the risks and benefits of a given health behavior as a 
precondition for embarking on changing behaviors (Bandura, 1977).  For ART adherence, it 
is important that people have some basic comprehension of the mechanisms of ART, that 
they understand the long-term nature of ART, and that they grasp the potential negative 
impact of non-adherence.  One study that specifically considered the association between 
knowledge of ART and adherence found that people with better ART knowledge were less 
likely to miss pills, compared with people with less ART knowledge (Weiss et al., 2003). In a 
longitudinal study in the United States, patients who had poor knowledge of their ART 
regimen at eight weeks after initiating treatment demonstrated poorer adherence (Miller et 
al., 2003). 
4. Outcome expectations of adherence 
Outcome expectations are what people expect will happen if they perform a given 
behavior. Outcome expectations may be either positive (expecting good things) or negative 
(expecting bad things). Positive outcome expectations increase the ‘pros’ of performing a 
behavior and therefore create incentives to perform a given behavior. These incentives may 
take the form of physical outcomes, social outcomes or self-sanctions (Fishbein, Triandis et 
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al, 2001). Negative outcome expectations increase the ‘cons’ of performing a behavior and 
therefore present barriers to achieving a behavior. When people begin taking ART, they most 
likely have some positive expectations of taking the drugs.  For example, they may expect 
that their health will improve, they will be able to return to work, or they will live longer. 
They may also have negative expectations, such as experiencing side effects, disrupting their 
normal routine, or having people find out that they are HIV-positive.  The balance of positive 
to negative outcome expectations, which may change over time, may influence patients’ 
motivation to adhere to ART. In a study in Brazil, low positive outcome expectations were 
associated with poor adherence (Pinheiro et al., 2002). 
Interpersonal level 
 People live in a social environment where they are constantly being influenced by 
other people. It is critical to understand these interpersonal influences on ART adherence. 
Although all of the variables below are measured at an individual level, their influence, and 
therefore subsequent interventions, are at an interpersonal level. 
5. Patient-provider interaction 
A good relationship between patients and health care providers is recognized as 
vitally important for positive health outcomes (C. Golin et al., 2008; Lewis et al., 2002).  
When health care providers use communication tools that empower patients to be involved in 
their own care, health outcomes can be improved (Trummer et al., 2006).  Positive 
interaction between patients and providers has been consistently associated with better 
adherence to ART in North American studies (Burke-Miller et al., 2006; Heckman et al., 
2004; Wroth et al., 2006).  Adherence is likely to be improved when patients feel they can 
ask questions and honestly share their experiences with health care providers, and when 
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providers listen to their patients and impart relevant information and skills (Schneider et al., 
2004).  
6. Perceived levels of social support 
Social support is positive assistance that is intentionally given from one person to 
another. As noted earlier, social support has been associated with adherence to medications 
in general (DiMatteo, 2004) and with adherence to ART in particular (Ammassari, Trotta et 
al., 2002).  The mechanisms through which social support exerts an influence on adherence 
have not been studied as often.  DiMatteo (2004) suggest that instrumental support may lead 
directly to adherence through the provision of practical support, while the relationship 
between emotional support and adherence may be mediated by a reduction in stress and 
depression, or an increase in self efficacy or self esteem.  
7. HIV and ART disclosure experiences 
Because of community-level stigma and fear of negative repercussions, many people 
do not disclose their HIV status to others (Blacker, 2004; Chandra et al., 2003; Petrak et al., 
2001).  Among women receiving HIV testing in a Dar es Salaam clinic, only 64% of those 
who tested positive disclosed their HIV status to their sexual partners (Maman et al., 2003). 
Among women who did not disclose, most reported that they were afraid of their partners’ 
reactions. If the response is positive, disclosing one’s HIV status to others – including family 
members, partners, friends and neighbors – may increase support for taking ART effectively. 
Hiding one’s HIV status, or failing to disclose that one is taking ART, may make it difficult 
to take ART on a regular basis, both because of not wanting to take ART in front of others 
and lacking outside cues for assistance. A qualitative study among ART patients in the rural 
US found that many patients missed doses because of fear of being identified as HIV-positive 
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(C. Golin, Isasi et al., 2002).  In Botswana, 69% of ART patients did not disclose their HIV 
status to their families and 94% did not disclose to people in their communities.  Failure to 
disclose was moderately associated with poor adherence (p=.07) (Weiser et al., 2003).   
Community level 
 While interpersonal influences deal with dyads, community influences deal with 
broader issues of group norms and cultural expectations. Again, while the variables below 
are measured at an individual level, their influence, and therefore subsequent interventions, 
occur at a community level. 
8. Perceived stigma towards people living with HIV 
Stigma is a prevailing societal judgment about a group of persons with a particular 
characteristic, which discredits these individuals and reduces them to lesser members of 
society (Goffman, 1963).  Researchers distinguish between perceived or felt stigma and 
enacted stigma, which refers to identifiable forms of discrimination. In a mixed-methods 
study conducted on HIV stigma in Ethiopia, Tanzania and Zambia,  people living with 
HIV/AIDS faced physical isolation from family, friends and community when their HIV 
status was known (Nyblade et al., 2003). Both perceived and enacted stigma led to isolation 
and a sense of hopelessness and resulted in the loss of access to physical and social 
resources. The study found that stigma resulted in people delaying HIV care until absolutely 
necessary and not getting the consistent care that was required. This impact of stigma could 
keep patients on ART from regularly attending clinic appointments and picking up their 
medications on time. In a South African study, ART patients who reported that they were 
afraid of being stigmatized by their sexual partners reported worse adherence than patients 
who did not express a fear of being stigmatized (Nachega et al., 2004). 
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9. Perceived normative beliefs of taking ART 
Normative beliefs refer to people’s beliefs about whether individuals in their 
reference group would approve or disapprove of a given behavior.  Normative beliefs make 
up a core construct of the theory of reasoned action (Montano et al., 2002), and are also 
inherent in the theoretical framework of social influence / interpersonal communication 
(Lewis et al., 2002). Normative beliefs of taking ART refer to whether people believe that 
others around them – family members, friends, religious leaders, physicians, etc. – approve 
or disapprove of their taking ART. Believing that most people in one’s reference group think 
that taking ART is a good thing, and having strong motivation to comply with those people’s 
beliefs, is likely to increase adherence to the medication.  The impact of normative beliefs on 
ART adherence has not been previously documented in the literature. 
Environmental level 
10. Clinic accessibility 
The SCT asserts that obstacles can make it nearly impossible to perform a health 
behavior, even if all other facilitators are in place. An obvious obstacle is physical 
accessibility to the clinic where one receives ART. Even with the strongest motivation, if 
people are not able to get to clinic appointments and pick up prescriptions on time, adherence 
can be impossible.  Clinic accessibility can be a barrier if patients live far from the clinic, if 
they travel and can not return for clinic appointments and drug pick-ups, if they can not 
afford transportation to the clinic, or if the clinic has operating hours that are incompatible 
with patients’ schedules. Difficulty finding or affording transportation to the clinic has been 
documented to negatively influence adherence (Hardon et al., 2007; Stout et al., 2004). 
  
Figure 3.6: Conceptual model of the multiple factors influencing ART adherence
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IV. STUDY OVERVIEW 
Study site 
The study took place at a health care facility in Arusha, Tanzania.  The facility is 
under the direction the Evangelical Lutheran Church of Tanzania, one of the major health 
care providers in Tanzania (Flessa, 1998).  The facility has been in operation since 1954 and 
includes a 120-bed hospital on the outskirts of the city and an outpatient clinic in the city 
center that houses the ART program.  The facility is guided by a mission to respond to the 
physical, psychological and spiritual needs of the patients it serves. 
Provision of ART at the study clinic began in October 2004, with funds from the 
United States’ PEPFAR program. The clinic offers free clinical services to HIV positive 
patients, including laboratory exams, treatment of opportunistic infections and ART.  Patients 
are eligible to start ART when their CD4 count drops below 200 or they present with 
opportunistic infections that represent a WHO clinical stage IV. At the time of the study, 
approximately 700 patients were receiving ART at the study clinic.   
In addition to clinical services, patients at the study clinic meet with a counselor 
every month when they come to pick up their prescription for ART.  At these brief meetings, 
the counselors discuss patients’ progress and any concerns they might have regarding their 
physical or social condition.  Patients are encouraged to bring a family member with them for 
their monthly appointments.  Patients are also paired with voluntary adherence counselors 
(VACs), who are HIV positive people trained to provide follow-up and support for clinic 
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patients. At the time of the study, 15 VACs were serving at the study clinic, and the clinic 
had plans to expand the program by training more VACs. 
The United States Agency for International Development, which provides support to 
the study clinic through PEPFAR, has recognized the study clinic as one of the best models 
of care for providing ART services in Tanzania.  In a reorganization of PEPFAR’s support to 
ART sites in 2006, the study clinic was one of just two sites that graduated from having 
third-party supervision to being directly supported by USAID. This organizational change 
was due to USAID’s perception that the study clinic had made significant progress in 
developing a comprehensive model of services for HIV positive individuals and that it had 
adequate organizational and human resource capacity to expand its provision of ART 
(Personal communication with USAID official, 2006). 
Methods  
Addressing the study aims required a combination of qualitative and quantitative 
methods. The use of mixed methods is valuable because it holds the potential to glean a fuller 
picture of the study topic and to transcend limitations in each of the methods (Borkan, 2004; 
Creswell et al., 2004; Steckler et al., 1992; Williamson et al., 2005).  The study was 
conducted in three phases (Table 4.1).  
 
Table 4.1:  Overview of research methods 
PHASE Method Sample size 
1 Semi-structured interviews with patients on ART, 
treatment supporters, health care providers and voluntary 
adherence counselors 
79 semi-structured interviews 
2 Home visits to patients who participated in the qualitative 
interviews 
42 home visits (2 visits each with 21 
patients ) 
3 Structured face-to-face survey with patients on ART 340 face-to-face survey interviews 
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All interviews were conducted in Kiswahili by trained Tanzanian researchers. With 
the exception of the home visits, all interviews were conducted in the clinic. The UNC 
Institutional Review Board, the Tanzanian Commission for Science and Technology, and the 
Tanzanian National Institute for Medical Research all reviewed and approved the study 
protocol. 
Introduction to the two manuscripts 
The first manuscript, entitled “Factors associated with self-reported adherence to 
antiretroviral therapy in Tanzania,” fulfills two functions. First, it presents the rate of 
adherence reported by the 340 patients who participated in the structured survey.  Second, it 
uses logistic regression to explore the factors associated with adherence.  Based on the high 
levels of optimal adherence reported in that sample, the second paper, entitled “It’s all the 
time in my mind: A qualitative exploration of factors that facilitate adherence to antiretroviral 
therapy in Tanzania,” uses the in-depth interviews with 36 patients and six health care 
providers to explore the factors that facilitated optimal ART adherence among patients in this 
clinic setting.   
This dissertation study aims to inform the efforts to expand and sustain ART services 
in Tanzania and beyond.  Survey data describes the population-based determinants of 
adherence, while qualitative information sheds light on the context of patients’ experiences 
taking ART, including how adherence is influenced by patients’ individual beliefs and 
motivations, social influences and routines of daily life. Together, this information can lead 
to the development of appropriate and effective interventions to support patients’ adherence 
to ART.  
 
 
 
V. MANUSCRIPT ONE: 
Factors associated with self-reported adherence to antiretroviral 
therapy in a Tanzanian setting 
 
Abstract 
Background:  Adherence to antiretroviral therapy (ART) is essential for clinical success 
among people living with HIV. The objective of this study was to determine the level of 
ART adherence and the factors associated with poor adherence among a convenience sample 
taken from a population of patients receiving free ART at one clinic in Tanzania. 
Methods:  Adult patients taking ART for at least one month were recruited into the cross-
sectional study from a single clinic in Arusha, Tanzania. Self-reported adherence over four 
days and one month were assessed by structured patient interviews. Patients who reported 
less than 95% on either of the measures were considered to have poor adherence. In addition 
to demographic and treatment variables, the following potential correlates of ART adherence 
were measured: perceived quality of patient-provider interaction, social support, perceived 
HIV stigma, self-efficacy to adhere, depression, number of people to whom patients had 
disclosed their HIV status, personal beliefs about ART, normative beliefs about ART, and 
perceived side effects.  Factors associated with adherence in unadjusted analyses (α=0.10) 
were considered in a logistic regression model in forward stepwise fashion.  
Results:  A total of 340 patients participated in the study.  Only 5.9% (20/340) of respondents 
reported less than 95% adherence in either the previous four days or one month. The final 
logistic regression model included the following factors significantly associated with poor 
adherence: being young (19-30 years old, vs. 31-40 years old; OR=4.26, 95% CI 1.33-13.60); 
  39
being old (over 50 years old, vs. 31-40 years old; OR=7.59, 95% CI 2.10-27.43); having 
lower perceived quality of patient-provider interaction (for each 1-point decrease in 
perceived quality of patient-provider interaction, OR=3.18, 95%CI 1.29-7.83); and reporting 
ever missing a clinic appointment (OR=3.75, 95% CI 1.29-10.89).  
Conclusions:  Adherence was very high in this sample. The factors associated with poor 
adherence highlight three specific needs: 1) to be sensitive to age-specific challenges of 
adherence and address these through appropriate counseling and support; 2) to be client-
focused and address patients’ perceived quality of patient-provider interaction; and 3) to 
emphasize and remind patients about clinic appointments. 
  
 
Introduction 
 Antiretroviral therapy (ART) to manage HIV infection is increasingly available 
throughout Africa.  Through an unprecedented international show of financial and political 
commitment to a health issue, ART coverage in Africa increased ten-fold in three years, from 
just 100,000 at the end of 2003 to over one million in mid-2006 (World Health Organization 
et al., 2006).  In Tanzania, where 6.5% of the adult population is living with HIV, ART 
coverage has expanded from less than 3,000 people at the end of 2004 to 54,000 people at the 
end of 2006 (UN Office for the Coordination of Humanitarian Affairs, 2007).  While access 
to medications is crucial, the success of the broad scale-up of treatment also depends on 
patients’ abilities to adhere to the drugs.  It is generally agreed that at least 95% adherence is 
needed to support clinical success to ART (Paterson et al., 2000).  Poor adherence can lead to 
viral resistance, the failure of cheaper first-line treatment regimens, and the spread of multi-
drug resistant forms of the virus (Bangsberg et al., 2000; Paterson et al., 2000; Stevens et al., 
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2004).  Understanding the prevalence of poor adherence and the factors that are associated 
with poor adherence are important clinical and public health goals. This information is 
essential to inform ART programs and maximize patients’ success on therapy.    
 A number of studies have been conducted in African settings to measure adherence to 
ART and explore the factors associated with adherence (Byakika-Tusiime et al., 2005; 
Diabate et al., 2007; Eholie et al., 2007; Laniece et al., 2003; Nachega et al., 2004; Orrell et 
al., 2003; Weiser et al., 2003).  In these studies, between 12% and 76% of patients failed to 
achieve optimal adherence, most often measured at a cut-off of 95%.  The variation in the 
adherence rates among these studies may in part be attributable to the variation in the 
conditions of the ART programs.  In the Senegal study, for example, where 76% of patients 
failed to achieve adequate adherence, a quarter of patients who missed pills said the reason 
was that the pharmacy was out of stock (Eholie et al., 2007).  In over half of the studies, 
patients were paying for pills out of pocket and their inability to consistently purchase pills 
was a substantial adherence barrier (Byakika-Tusiime et al., 2005; Eholie et al., 2007; 
Laniece et al., 2003; Weiser et al., 2003). Despite these structural barriers, a meta-analysis 
demonstrated that, overall, the adherence to ART of patients in African settings exceeded 
that observed in North American settings (a pooled estimate of 77% of participants in 
African studies achieving adherence vs. 55% of patients in North American studies) (Mills, 
Nachega, Buchan et al., 2006).  
Most studies that have explored the factors associated with adherence to ART in 
African settings have been cross-sectional and measured adherence by self report.  They have 
identified poor adherence as associated with: demographics (having low income, being 
single, being young, higher education, language spoken); psychological factors (low HIV 
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optimism, lack of a lifetime commitment to ART); inter-personal factors (social support, fear 
of stigma); treatment-related factors (number of pills, number of doses, higher CD4 count at 
initiation of ART, ART regimen); and facility-related factors (cost of treatment).  Studies in 
developed countries similarly have found that adherence is influenced by variables at 
multiple levels of the social-ecological framework (SEF), including factors inherent to the 
individual, the individual’s relationships, and the clinic environment, as well as 
characteristics of the regimen itself (Ammassari, Trotta et al., 2002; M. Chesney, 2003; 
Fogarty et al., 2002; Ickovics et al., 2002a; Mills, Nachega, Bangsberg et al., 2006; Sankar et 
al., 2006; Vervoort et al., 2007).  This evidence points to the need to understand and address 
potential barriers associated with adherence at multiple levels of influence. 
 This study is the first to assess the factors associated with adherence to ART in 
Tanzania.  It is also the first study to look at these issues in an African setting where all 
patients are receiving free services and the large majority are taking single-pill, twice-a-day 
combinations of ART. The study addressed two research questions: (1) what proportion of 
patients achieved at least 95% adherence to ART; and (2) what factors are independently 
associated with having less than 95% adherence. The findings may be used to improve both 
existing and new ART programs in Tanzania and to inform further research.  
Methods 
Study site 
 The study took place at an urban, faith-based clinic in Northern Tanzania.  With 
financial support from the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR), the 
clinic provides free ART and related services (laboratory tests and treatment of opportunistic 
infections) to all HIV-positive patients with a CD4 measurement of less than 200 or a WHO 
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clinical stage of IV. All patients at the study clinic are counseled about adherence before 
initiating ART and while taking therapy. In addition, patients are paired with HIV-positive 
peers who provide informational and emotional support.  At the time of the study, 
approximately 700 adults were receiving ART from the clinic where this study was 
conducted. 
Data collection 
HIV-positive patients at the study clinic participated in a cross-sectional interviewer-
administered face-to-face survey.  Patients were eligible to participate in the study if they 
were 18 years or older, had been taking ART for at least one month, and had not participated 
in the qualitative phase of the study. 
For a four week period, we consecutively approached all adult patients who came to 
the clinic to pick up their monthly supply of ART on designated HIV clinic days (Monday, 
Wednesday and Friday). The pharmacist screened all patients for eligibility and gave eligible 
patients a colored piece of paper, which indicated to a recruiter stationed next to the 
pharmacy that the patient was eligible to participate in the study. The recruiter told all 
eligible patients briefly about the study and, if they were interested in participating, referred 
them to an interviewer.  
The Tanzanian interviewers, who had received standardized training, read an 
informed consent form to participants and administered the questionnaire orally in Kiswahili 
to those who provided written consent.  To facilitate responses on scaled questions, 
interviewers used a visual aid that included circles of increasing sizes with the written 
response options underneath. Respondents could view the relative magnitude of the response 
choices and point to the appropriate circle to indicate their responses. Participants received 
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5,000 Tanzanian Shillings (approximately 4 US dollars) for participating in the one-hour 
survey. 
The Institutional Review Boards of the University of North Carolina School of Public 
Health, the Tanzanian Commission for 
Science and Technology and the 
Tanzanian National Institute for Medical 
Research all reviewed and approved this 
study. 
Measurements 
 The survey instrument was 
developed based on standard 
measurement scales and preliminary 
findings from the formative phase of the 
study (69 in-depth qualitative interviews 
about ART adherence conducted with 
patients, treatment supporters, health care  
providers and HIV-positive counselors). 
Table 5.1 lists the factors measured in the 
survey. All questionnaire items and 
response choices were translated into 
Kiswahili and back-translated into English. We conducted ten cognitive interviews with HIV 
positive patients to assess comprehension of individual questions. We pre-tested the 
 Table 5.1: Factors measured in the cross-
sectional survey, with Chronbach’s alpha 
reported for scale measures 
 
   
 Outcome variable  
Self-reported adherence to ART 
   
 Correlates  
Perceived quality of patient-provider 
interaction (α=.791) 
Social support (α=.858) 
Perceived HIV stigma (α=.899) 
Self-efficacy to adhere (α=.720) 
Depression (α=.846) 
Extent of HIV disclosure  
Personal beliefs about ART 
Normative beliefs about ART 
Skills used to adhere 
Perceived side effects 
   
 Treatment-related variables  
Time on ART 
ART regimen 
   
 Demographics  
Sex 
Age 
Religion 
Education 
Relationship status 
Socio-economic status 
Clinic accessibility 
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questionnaire with 40 patients to assess the flow, timing and comprehension of the entire 
instrument.  
Adherence 
Development of adherence measure 
The self-reported adherence measure was developed through multiple home visits to 
21 ART patients who had participated in the qualitative phase of the research, using pill 
count as an objective criterion to validate the self-report measure. At the first home visit, the 
local interviewer observed where the participant kept his or her medication and recorded a 
pill count. At the second visit four days later, the interviewer administered three self-reported 
adherence measures: a four-day recall, a one-month linear visual analogue scale, and a one-
month modified visual analogue scale using a jar of beads (method described below). 
Following each measure, the patient was asked to explain why they answered the way they 
did and whether they understood the question well. The interviewer then asked again to see 
the patient’s medication and made a note of the number of pills left in the container. The 
results of the four-day pill count were compared with the results of the four-day self-report. 
In all but one case (95.2%) the four-day self report and pill count provided the same result. 
Patients reported confusion about the linear visual analogue scale, leading to the selection of 
the modified visual analogue scale using a jar of beads. 
Description of adherence measure 
 Self-reported adherence to ART was measured with two sets of questions: a four-day 
recall and a modified one-month visual analogue scale (VAS).  The four-day recall of 
adherence was adapted from the AACTG Adherence Instrument, developed for use in 
clinical trials conducted in the United States (M. A. Chesney, Ickovics et al., 2000) and 
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adapted in multiple studies on the correlates of adherence in the U.S. and in Africa (Byakika-
Tusiime et al., 2005; Nachega et al., 2004; Nemes et al., 2004; Weiss et al., 2003).  The 
interviewer began by asking respondents to identify the regimen they were currently taking, 
using pill bottles to aid responses.  The interviewer then confirmed with patients at what 
times of day they took their pills and the number of pills per dose.  For each dosing period 
over the previous four days, the interviewer used memory recall prompts (e.g., asking 
respondents what time they woke up or what time they ate dinner that evening) and then 
asked whether they took morning and evening doses and, if so, at what time.   
The one-month measure of adherence was based on the concept of a linear visual 
analogue scale (VAS), which asks respondents to indicate on a line on a piece of paper the 
proportion of prescribed ART pills they took in the previous month, from 0 to 100% (Walsh 
et al., 2002).  We modified the VAS scale by using a visual tool of a jar of beads (Hardon et 
al., 2006). The interviewer explained that the jar contained the number of pills they should 
have taken in the previous month, and asked them to transfer to another jar the number of 
pills they actually did take in the previous month.  The proportion of pills that respondents 
transferred from one bottle to another was an estimate of their adherence for the previous 
month. 
The group of adherence questions was preceded by a statement acknowledging that 
people may miss taking pills for a variety of reasons and encouraging full disclosure of non-
adherence.  For any reported missed pills, the interviewer asked an open-ended question of 
why they had missed their pills. 
Adherence was dichotomized to consider whether or not respondents had achieved 
optimal adherence.  Optimal adherence was defined as reporting 95% adherence on both the 
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4-day and one-month recalls, while sub-optimal adherence was defined as failing to achieve 
95% adherence on one or both measures. 
Correlates  
 The potential correlate variables to study were chosen based on a theoretical 
framework drawing upon the Social Cognitive Theory (Baranowski et al., 2002) and the 
construct of social support (Heaney et al., 2002).  
Perceived quality of patient-provider interaction was measured with a 9-item scale 
adapted from a study in Thailand (Panpanich et al., 2004). Items asked how much patients 
agreed with statements about their interactions with health care providers (staff give you 
enough time every time you come to the clinic; staff are willing to listen to your problems or 
your concerns; staff help you find solutions to health problems; staff explain things in a way 
you understand; you are able to contact staff when you need to; you are comfortable talking 
openly with staff; you get good care for your conditions from staff; staff provide advice for 
problems you have taking your medications; staff understand the difficulties you face taking 
your pills; and staff encourage you to take your pills) (α =.791).  One additional question was 
dropped from the scale because it didn’t load on the factor (staff advise you on how to reduce 
side effects to ARVs). 
Social support was measured with a modified version of the Medical Outcomes Study 
(MOS) social support scale (Sherbourne et al., 1991). In addition to using the eight questions 
from the emotional/informational support sub-scale and the four questions from the tangible 
support sub-scale, we included five additional questions based on the types of support people 
mentioned during the qualitative interviews as important (how often do you feel you have: 
someone to remind you to take your pills; someone to give you courage in living with HIV; 
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someone to pick up your pills from the clinic if you’re not able; someone to give you 
spiritual help; and someone to give you money if you don’t have it). The questions about 
spiritual help and money were dropped on the final scale because they didn’t load on the 
factor (α =.858).  
Perceived HIV stigma was measured by adapting a 10-question scale on experienced 
stigma developed in a Tanzanian context (Nyblade et al., 2003).  Items asked how worried 
respondents were about particular negative consequences if other people knew their HIV 
status (e.g., how worried are you that you would be excluded from a social gathering if 
people knew your HIV status) (α =.899).  
Self-efficacy to adhere was measured with a 10-item scale adapted from studies in 
Thailand and Brazil (Panpanich et al., 2004; Pinheiro et al., 2002) and informed by the 
qualitative data.  The scale included 9 items, each assessing respondents’ confidence to take 
their HIV medication given a challenging situation (e.g., when you feel very healthy; when 
you are away from home) (α =.720).  
Depression was measured using the 11 items that make up the psychological sub-
scale of the Hopkins Symptoms Checklist that has been validated in the Tanzanian context 
(Kaaya et al., 2002). The items asked how often respondents had experienced depressive 
symptoms in the previous month (e.g., felt lonely, worried too much about things, cried 
easily) (α =.846).  
The extent of disclosure of one’s HIV status was measured with a single question: 
How many people have you talked with about your HIV status?  HIV disclosure was 
analyzed both as a dichotomous measure of whether or not patients had disclosed to anyone 
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and also as a categorical measure of how many people they had spoken with about their HIV 
status (no one, one person, two people, three or more people).  
Personal beliefs about ART were measured with a set of eight questions, informed by 
the qualitative instrument, each assessing what patients know or believe about ART (e.g., 
whether ART can completely remove HIV from the body; whether ART are for life; and how 
ART impact CD4 and viral load). Beliefs about ART were measured as a continuous variable 
of the number of questions where patients expressed incorrect knowledge in their beliefs. 
Normative beliefs about ART  were measured with three questions: whether 
respondents had ever been told that taking ART would make them die sooner; whether they 
had been told that they should take traditional medicines instead of ART; and whether they 
had been told that they should pray instead of taking ART.   
Skills used to adhere were measured with a set of six questions, informed by the 
qualitative interviews, about whether respondents had used different skills to remember to 
take their ART over the past month (e.g., listening to the radio, setting an alarm).   
Perceived side effects were assessed with a single question of whether respondents 
had experienced any side effects related to their medication over the past month.  
Treatment-related variables 
Length of time on ART was measured with a single question asking when patients 
started taking ART. If respondents did not know the month and year, the interviewer checked 
their treatment card, which all patients must present at the pharmacy.  ART regimen was 
measured with a single question. Interviewers presented respondents with pill bottles to assist 
in correct identification of the regimen.  
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Demographics 
 We measured sex, age, religion, highest level of education and current relationship 
status. Socio-economic status (SES) was calculated by a weighted sum of nine ownership 
items (radio, telephone, television, bicycle, car, refrigerator, cows, small animals, or a plot of 
land), electricity in the house, indoor plumbing, and a single question about food security in 
the previous month.  Weights were assigned to individual SES items based on principal 
coordinate analysis (Bangdiwala et al., 2004). To assess clinic accessibility, we analyzed 
separately questions about how much time respondents spent traveling from their home to the 
clinic and how much it cost them to travel from their home to the clinic. 
Data management and analysis 
Data were double-entered in an Access database and compared for keystroke errors 
using Epi Compare. SPSS version 15.0 (SPSS Inc. Chicago, IL) was used for all analyses.  
Scaled measures were reviewed for internal consistency (reporting Chronbach’s alpha) and 
item-by-item analysis was conducted to consider any items that should be dropped from the 
scales. Overall scaled scores were calculated by averaging the item responses and imputing 
missing responses.  Scale items had, on average, fewer than two missing cases. 
Logistic regression was used for analysis of unadjusted log odds of less than 95% 
adherence. Factors that were significantly associated with adherence at α =0.10 were 
considered in a multiple logistic regression model, as were potential control variables (sex, 
time on ART and SES) that affected the point estimate of predictor variables by +/-10%.   
The model was built with forward iterations, considering the limitation that five outcome 
events are required per predictor variable (Vittinghoff et al., 2007). Adjusted odds ratios and 
95% confidence intervals are presented in the final model for the variables.  Goodness of fit 
  50
of the final model was assessed using the 
Hosmer and Lemeshow test.  Non-
significance of the chi square statistic from 
this test supported the model (Kinnear et al., 
2006). Variables included in the final model 
were empirically investigated for 
multicollinearity. 
Results 
Sample demographics 
A total of 340 patients participated in 
the cross-sectional survey. An additional 17 
eligible patients (4.8%) were approached by 
the recruiter but declined to participate. The 
primary reason for declining was not having 
time available to complete the survey.  
Table 5.2 describes the demographic 
characteristics of the study sample.  The 
predominance of females in our sample was 
representative of patients receiving ART at 
the study clinic. The average age of participants was 39.5 years (range 19 to 77).  Male 
respondents were on average older than female respondents (42.5 years vs. 38.4 years, 
p<.001).   
 Table 5.2: Demographic characteristics of 
respondents (n=340) 
 
  n %  
 Sex    
Male 88 25.9%  
Female 252 74.1%  
     
 Age    
19-30 54 15.9%  
31-40 160 47.1%  
41-50 91 26.8%  
51 and older 34 10.0%  
     
 Education    
Did not complete 
primary  
69 20.3%  
Completed primary only 207 60.9%  
More than primary  64 18.8%  
     
 Religion    
Christian 74 78.0%  
Muslim 263 22.0%  
     
 Electricity in house    
Yes 110 32.4%  
No 230 67.6%  
     
 Indoor plumbing    
Yes 56 16.7%  
No 283 83.3%  
     
 Problems getting food in 
past month 
   
Yes 242 71.4%  
No 97 28.6%  
     
 Time to reach clinic    
< 1 hour 152 44.8%  
> 1 hour 187 55.2%  
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Patients had been taking ART for an average of 13.9 months (range 1 to 62). The 
majority (311/340, 91.5%) were taking Triomune (manufactured by Cipla in Mumbai, India), 
a twice-a-day single combination ART pill containing Stavudine, Lamivudine and 
Nevirapine.  An additional 27 respondents (7.9%) reported taking a two-pill combination of 
Combivir, containing Lamivudine and Zidovudine, and Efavirenz. This combination was 
usually prescribed to patients who were not tolerant of the Nevirapine contained in 
Triomune. The remaining two patients reported taking other ART combinations. 
Adherence 
 Adherence in this setting was high, with 320 out of 340 respondents (94.1%) 
reporting at least 95% adherence on both the four-day and one-month self-report measures 
(Table 5.3). Of the 20 respondents who were classified as having poor adherence, 12 reported 
less than 95% adherence on the four-day measure, five reported less than 95% adherence on 
the one-month measure, and three reported less than 95% adherence on both measures. When 
asked why they had missed their pills, the most common response was that they simply 
forgot (45%), followed by being out of the house or traveling (20%), running out of pills 
because they had not come to the clinic on time for a refill (9%), intentionally not taking their 
pills due to illness or side effects (8%), or oversleeping (5%).  
 Table 5.3: Self-reported sub-optimal adherence by 4-day, 
one-month and cumulative measures (n=340) 
 
  n %  
 Respondents with <95% adherence    
4-day recall 15 4.4%  
One-month estimate 8 2.4%  
Cumulative  20 5.9% 
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Correlates of adherence 
Results from bivariate associations of our correlate, demographic and treatment 
variables with our outcome variable included six significant factors at α=0.10: age (being 19-
30 years old or older than 51); having less than standard 7 education; having never been 
married; having lower self efficacy to adhere; reporting lower perceived quality of patient-
provider interaction; and reporting having ever missed a clinic appointment (Table 5.4). The 
following correlate variables were not associated with adherence in our sample: social 
support, perceived stigma, depression, extent of HIV disclosure, normative beliefs about 
ART, personal beliefs about ART, skills used to adhere, and side effects. 
The variables that were associated with adherence in the bivariate analysis at the 0.10 
level or lower were considered in the multiple logistic regression model. The final model 
included three significant variables: age, missing a clinic appointment, and perceived quality 
of patient-provider interaction (Table 5.4).  Marital status, education and self efficacy to 
adhere were not significant when controlling for the other variables, and were therefore not 
included in the final model. Missing a clinic appointment and perceived quality of patient-
provider interaction were correlated, with patients who reported ever missing a clinic 
appointment having lower perceived quality of patient-provider interactions, compared with 
patients who reported never missing a clinic appointment (F=21.07, p<.001).  When we 
included the interaction term of the two items in the model, it was not significant and was 
therefore not retained. 
In the final model, age exhibited a U-shaped relationship with adherence. 
Respondents aged 19-30 years old were over four times more likely to report poor adherence, 
compared with respondents aged 31-40 (OR=4.26, 95%CI 1.33-13.60) and respondents over 
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age 50 were over seven times more likely to report poor adherence, compared with 
respondents aged 31-40 (OR=7.59, 95% CI 2.10-27.43).  Perceived quality of patient-
provider interaction was also significantly associated with adherence. For each one-point 
decrease in the four-point scale, respondents were three times more likely to report poor 
adherence (OR=3.18, 95% CI 1.29-7.83).  Finally, respondents who reported ever missing a 
clinic appointment were almost four times more likely to report poor adherence, compared 
with respondents who said they had never missed a clinic appointment (OR=3.75, 95% CI 
1.29-10.89).   
Discussion 
Adherence was very high in this setting, with 94.1% of patients reporting that they 
took at least 95% of their prescribed pills during both the previous four days and previous 
one month. The rate of adherence in our sample was significantly higher than has been 
observed in other studies in African settings that also relied upon self report (Byakika-
Tusiime et al., 2005; Diabate et al., 2007; Eholie et al., 2007; Laniece et al., 2003; Nachega 
et al., 2004; Weiser et al., 2003).  The high adherence may be attributable to the nature of the 
study site.  While most previous studies have been conducted in large government hospitals 
in capital cities, this study was conducted in a small faith-based clinic, which may have 
offered patients more personal attention.  In addition, it is possible that the simple regimen 
(almost all patients were taking regimens that required just one pill twice a day) facilitated 
adherence. In previous studies in Africa, patients were taking regimens that included multiple 
pills at two or more dosing intervals.  An increasing number of pills and doses has been 
associated with worse adherence (Ammassari, Trotta et al., 2002; M. Chesney, 2003; Diabate 
et al., 2007; Laniece et al., 2003; Orrell et al., 2003). Finally, while previous studies in Africa 
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have often included patients who were paying out-of-pocket for ART drugs or related 
services, all HIV-related care at this site was offered free of charge to patients.  Studies have 
consistently shown that ART adherence is higher when cost is not an obstacle (Byakika-
Tusiime et al., 2005; Eholie et al., 2007; Weiser et al., 2003). 
Several factors were associated with adherence in this sample. Both respondents who 
were younger (19 to 30 years old) and respondents who were older (50 years or more) were 
more likely to report poor adherence, compared with respondents ages 31 to 40. Younger age 
has been associated with poor adherence in other African studies (Diabate et al., 2007; Orrell 
et al., 2003), in Brazil (Nemes et al., 2004), and in India (Shah et al., 2007), as well as in 
North American settings (Barclay et al., 2007; Murphy et al., 2004; Schneider et al., 2004; 
Sullivan et al., 2007).  The finding that young people were less likely to adhere was possibly 
related to younger people having less stable social and economic situations than their older 
counterparts and having less experience interacting with the health care system.  The 
association between older age and poor adherence has not been documented elsewhere.  A 
review of HIV infection among older people points out that scant attention has been given to 
the impact of the HIV epidemic on the older population (Knodel et al., 2003). The invisibility 
of older people in the epidemic is evident in the statistics published by UNAIDS, which 
reports HIV prevalence only among children (0-14 years) and “adults” (15-49 years), 
neglecting older people living with HIV (UNAIDS et al., 2006). More attention needs to be 
given to understanding the challenges faced by older individuals living with HIV and their 
experiences taking ART.  Age- and sex-specific prevalence of HIV in Tanzania showed that 
women are infected at younger ages than men (Tanzanian Commission for AIDS et al., 
2005), but there was no significant interaction between age and sex in the model.  
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Patients with less favorable assessments of their interactions with providers had 
worse adherence in this sample.  Evidence from Africa confirms that patients value personal 
connections with providers, sometimes prioritizing the interpersonal domain over technical 
aspects of care (S. Haddad et al., 1995; S. Haddad et al., 1998; Unger et al., 2002). The 
association between adherence and patient-provider interaction has not been explored in 
other African studies, but has been identified in North American settings in both quantitative 
(Burke-Miller et al., 2006; Heckman et al., 2004; Schneider et al., 2004; Wroth et al., 2006) 
and qualitative studies (Abel et al., 2003; C. Golin, Isasi et al., 2002; Malcolm et al., 2003; 
Murphy et al., 2003; Murphy et al., 2000; Remien et al., 2003; Roberts, 2002; Sankar et al., 
2002).  Communication between patients and health care providers is recognized as vitally 
important for good health outcomes (C. Golin et al., 2008; Lewis et al., 2002).  Adherence is 
likely to be improved when patients feel they can ask questions and honestly share their 
experiences with health care providers, when providers listen to their patients and impart 
relevant information and skills, and when providers exhibit warmth and empathy (Schneider 
et al., 2004; Squier, 1990). The successful use of motivational interviewing by health care 
providers in North American settings offers further support to the positive impact of patient-
provider communication on adherence (Adamian et al., 2004; Cooperman et al., 2005). The 
quality of patient-provider interactions will be all the more important – and more challenging 
– as more patients enroll in ART programs, particularly given the shortage of health care 
workers throughout sub-Saharan Africa (Barnighausen et al., 2007; Kumar, 2007). Further 
research is needed to understand the aspects of patient-provider interactions most valued by 
patients in the Tanzanian setting, as well as the mechanisms through which patients’ 
assessments of their interactions influence adherence outcomes. 
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Reporting ever missing a clinic appointment was associated with poor adherence.   
We do not have information about the reasons that patients missed appointments, but the fact 
that neither the amount of time nor the amount of money spent to reach the clinic were 
associated with adherence suggests that missing clinic appointments may be a function of 
personal motivation, rather than structural barriers of access, as have been identified in other 
studies (Hardon et al., 2007; Rosen, Ketlhapile et al., 2007). Missing a clinic appointment 
was associated with perceived quality of patient-provider interaction, with patients who 
missed appointments reporting lower perceived quality of interaction with their providers. 
The interaction between these two variables was not significant in the model of poor 
adherence, which may be attributable to the lack of power in the study due to the small 
number reporting poor adherence. More research is needed, ideally through a longitudinal 
study, to understand why patients miss clinic appointments and how or whether missed visits 
affect adherence or are just markers for other domains. Given the evidence of high loss to 
follow up in African ART programs, understanding and addressing missed appointments is 
of particular concern in and of itself (Rosen, Fox et al., 2007). 
All other variables measured in the survey were not independently associated with 
adherence.  However, this does not mean that these other psychosocial factors are not 
important to address in ART programs. Factors such as depression, stigma, disclosure and 
social support play important roles in the lives of people living with HIV, and successful 
ART programs should seek to positively influence these domains (Remien et al., 2007).  
Even though these factors did not distinguish good adherers from poor adherers in this 
setting, they likely have an impact on the quality of life of people living with HIV and may 
influence patients’ retention in ART programs (Rosen, Fox et al., 2007).  The scale measures 
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adapted and developed for this study demonstrated strong internal reliability, suggesting that 
a lack of significance is not attributable to their measurement.  The replication of these 
measures may be warranted in other studies with larger samples exploring these domains. 
The findings highlight areas where interventions may be useful to improve adherence.  
First, counselors and health care providers should be aware that younger and older patients 
may have particular challenges adhering to their medications.  They should seek to 
understand and respond to these challenges through directed counseling. Second, ART 
programs should make efforts to be client-focused and regularly assess and address the 
quality of interactions between providers and patients. This should be done at both the 
institutional level, for example in the time allotted for providers to spend with patients, as 
well as the interpersonal level of communication between providers and patients. Third, ART 
programs should emphasize to patients the importance of attending clinic appointment and 
look at innovative ways to remind patients about their appointments and assess and remove 
any barriers they face.  Finally, the fact that the most common response to why patients had 
missed taking their pills was that they “just forgot” highlights the potential value of 
identifying appropriate reminder strategies, such as alarms, cell phone text messages, pill 
boxes, or engagement of household members to provide reminders (C. E. Golin, Liu et al., 
2002a; Safren et al., 2003).  
The results of this study must be interpreted in the context of its limitations. Although 
self-reported measures of adherence have been consistently correlated with viral load 
(Arnsten et al., 2001; Duong et al., 2001; Fairley et al., 2005; Fletcher et al., 2005; Liu et al., 
2001) and have been deemed as robust and appropriate indicators of adherence (Simoni et al., 
2006), they are nevertheless subject to social desirability and recall bias, and as such may 
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under-estimate non-adherence compared with more objective measures such as pill counts 
and the use of electronic pill caps (Arnsten et al., 2001; M. A. Chesney, Ickovics et al., 2000; 
Liu et al., 2001; Reynolds, 2004; G. Wagner et al., 2004; G. J. Wagner et al., 2000).  The fact 
that this study was cross-sectional means that it was impossible to establish temporal 
relationships. The study also failed to capture patients who had dropped out of the ART 
program altogether; by doing so, it may over-estimate adherence.  Previous research in 
Africa has found that only 60% of patients who enter ART programs in Africa remained 
enrolled at two years, with loss to follow up accounting for over half of the attrition (Rosen, 
Fox et al., 2007).   
The recruitment strategy employed in this study introduced the possibility of 
systematic bias and may have over-estimated adherence.  The primary reason that patients 
declined to participate was being too busy, which may indicate that this group was different 
than patients who participated in the survey, with those who declined having less time 
available to attend clinic appointments and therefore having worse adherence.  Additionally, 
we did not interview people who were picking up medication for someone other than 
themselves, which may mean that we missed patients who were too sick to attend their clinic 
appointments.  Patients who missed their clinic appointments during the four-week 
recruitment period were also not included.  Finally, we were not able to compare recruitment 
to the clinic roster and therefore lack information on which patients we missed approaching 
altogether.     
Given the high adherence in the sample, there was limited power to detect differences 
between those who achieved adherence and those who failed to achieve adherence. The small 
number of poor adherers limited the number of predictors that could be considered in the 
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final model and precluded the possibility of examining interaction terms. The allowance of 
five outcome events per predictor variable was acceptable (Vittinghoff et al., 2007), but not 
as conservative as other recommendations that ten outcome events are necessary per 
predictor variable (Peduzzi et al., 1996).  Following the recommendation of five outcome 
events per predicator variable could have resulted in finding associations that did not exist 
(type I error).  
Future studies of this type should include a larger sample size to provide more power 
to detect significant relationships.  Longitudinal studies are needed in this setting to 
understand adherence over time and to explore the factors associated with discontinuation of 
therapy.  It might also be beneficial to conduct qualitative and quantitative research to 
establish a ‘best practice’ for measuring adherence by self report in this setting.   
This is the first study to look at correlates of ART adherence in Tanzania.  It is also 
the first study of this type among a population receiving free ART and where almost all 
patients are taking a simple regimen of one combination ART pill twice per day. The results 
document encouraging high levels of adherence.  The factors associated with adherence 
highlight the importance of understanding age-related factors that may influence adherence, 
of providing patient-centered quality services, and of ensuring adequate clinic access and 
follow-up to eliminate missed appointments.   
  
 
Table 5.4: Factors associated with reporting <95% adherence. The adjusted model used forward stepwise regression to find the best four-factor 
model to predict <95% adherence. 
 
 n % <95% 
adherence 
Unadjusted OR (95% CI) p-value Adjusted OR (95% CI) p-value 
Age        
19-30 years 54 11.1% 3.80 (1.26 – 11.44) .018 4.26 (1.33 – 13.60) .015 
31-50 years 251 3.2% REF  REF  
51 years and older 34 14.7% 5.24 (1.61 – 17.08) .006 7.59 (2.10 – 27.43) .002 
       
Education       
Did not complete primary  69 10.1% 2.24 (.86 – 5.85) .083   
Completed primary 271 4.8% REF    
       
Marital status        
Married 128 5.5% REF    
Single, never married 30 16.7% 3.46 (1.011 – 11.78) .047   
Divorced or separated 83 3.6% 0.65 (.16 – 2.58) .539   
Widowed 99 5.1% 0.92 (.28 – 2.99) .889   
       
Missed clinic appointment        
Never missed appointment 280 3.9% REF  REF  
Ever missed appointment  60 15.0% 4.32 (1.70 – 10.94) .002 3.75 (1.29 – 10.89) .015 
       
Self efficacy to adhere        
For each 1-point decrease   3.84 (1.42 – 10.36) .008   
       
Perceived quality of patient-provider interaction     
For each 1-point decrease   3.48 (1.56 – 7.78) .002 3.18 (1.29 – 7.83) .012 
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VI. MANUSCRIPT TWO: 
“It’s all the time in my mind”: 
A qualitative exploration of factors that facilitate adherence to 
antiretroviral therapy in a Tanzanian setting  
 
Abstract 
Background:  Studies show that HIV-positive patients’ adherence to antiretroviral therapy 
(ART) is relatively high in African settings, but few have explored factors that facilitate 
adherence. Qualitative research that is informed by behavioral theory can help explain how 
and why patients adhere to ART. Understanding the dynamics of good adherence to ART 
may contribute to improving and sustaining high adherence. 
Methods:  The study was conducted at a faith-based clinic in Arusha, Tanzania, where 
participants were receiving free ART and HIV-related clinical services. Individual semi-
structured interviews were conducted with 6 health care providers and 36 patients at the 
study site. All providers who spent the majority of time giving direct care to ART patients 
were eligible to participate. The patient sample was selected to include equal representation 
of men and women at various times on ART.  Interviews were conducted in Swahili using 
interview guides informed by the Social Cognitive Theory.  All interviews were audio-
recorded, transcribed in Kiswahili, translated into English and coded for themes and patterns 
with Atlas t.i.  
Results: Of the 36 patients (mean time on ART 9.8 months; range 1-23months), 32 reported 
perfect adherence in the previous month, three reported 98% adherence, and only one 
reported less than 95% adherence. Self-reported adherence was high despite potential barriers 
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of economic hardship, depression, low rates of HIV disclosure and high perceived HIV-
associated stigma. Five factors emerged to explain excellent adherence.  First, all respondents 
experienced substantial improvements in their health after starting ART, which increased 
their confidence in the medication and motivated them to adhere.  Second, respondents 
developed specific strategies to remember to take pills, particularly routinizing pill-taking by 
linking it with daily activities or events. Third, their perceived need to be able to meet their 
family responsibilities motivated respondents to stay healthy. Fourth, material and emotional 
support received from others facilitated adherence. Finally, respondents trusted the advice 
and instructions of their health care providers, who regularly emphasized adherence. 
Interviews with providers suggested that their interactions with patients reinforced patients’ 
own motivations and mechanisms to adhere.  
Conclusions: Almost all patients in this setting reported excellent ART adherence, despite the 
presence of potential barriers to adherence.  The facilitating factors identified were consistent 
with the constructs of the Social Cognitive Theory to explain health behavior and highlight 
the importance of interventions that address multiple levels of influence on adherence.  
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Introduction 
In 2007, 2.1 million people worldwide died from HIV and AIDS-related illnesses, 
with over 75% of those deaths occurring in Africa (UNAIDS, 2007). Antiretroviral therapy 
(ART) offers an unprecedented opportunity to avert deaths of people living with HIV/AIDS, 
and funds and political will have been mobilized to make ART available where it is most 
needed. In Tanzania, where approximately two million people (6.5% of the adult population) 
are living with HIV (UNAIDS et al., 2006), the government is committed to making free 
ART available to as many residents as possible (Government of Tanzania, 2003). Currently 
54,000 people are receiving ART at 200 sites across the country (UN Office for the 
Coordination of Humanitarian Affairs, 2007). 
The success of a national scale-up of ART depends on bolstering the capacity and 
reach of the health care system and shifting the system’s orientation from an acute 
management model to a chronic care model (Swartz et al., 2002; World Health Organization, 
2002a).  At the same time, success on ART depends on patients’ abilities to adhere to 
medications, which are influenced by factors extending beyond the clinic environment. Poor 
adherence can lead to the virologic failure of cheaper first-line treatment regimens and the 
spread of multi-drug resistant forms of the virus, resulting in a public health calamity 
(Paterson et al., 2000; Stevens et al., 2004).  Poor adherence to all chronic therapies results in 
increased costs to health and society, in terms of direct financial costs of failed treatment and 
higher hospitalization rates, and indirect costs of lost productivity of patients and burden on 
family caregivers (Dunbar-Jacob et al., 2000; Sokol et al., 2005). The impact of sub-optimal 
adherence to ART is particularly concerning in countries that lack the capacity for regular 
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viral load testing to detect drug resistance and where second-line regimens are prohibitively 
expensive or not available (Cohen, 2007).   
Poor adherence to medication is a problem across chronic conditions.  The World 
Health Organization, in a comprehensive report of adherence to long-term therapies, 
estimated that just 50% of patients in developed countries were adherent to chronic therapies. 
They speculated that adherence may be even lower in developing countries, where issues of 
unreliable supply and financial barriers to access present additional challenges (World Health 
Organization, 2003). Initial findings about patients’ adherence to ART regimens in sub-
Saharan Africa, however, show promising outcomes. A meta-analysis of studies on ART 
adherence found that a pooled estimate of 77% of patients in African settings achieved 
adequate adherence (most often measured as taking 95% of prescribed pills), compared with 
just 55% of patients in North American settings (Mills, Nachega, Buchan et al., 2006).  A 
survey of 340 patients in the study site discussed in this article found that 94.1% of patients 
reported taking at least 95% of their pills over the previous four-day and one-month periods 
(Watt, unpublished).   
At the same time as we are observing good adherence, there is evidence that retention 
in ART programs may be low.  A meta-analysis of ART programs in Africa suggested that 
only 60% of patients remained enrolled in programs at the end of two years.  The ambiguous 
category of “loss to follow up” accounted for 56% of attrition (Rosen, Fox et al., 2007). The 
potentially high levels of drop out from ART programs indicate that we require a better 
understanding of patients’ experiences taking ART.  Understanding how patients integrate 
ART in the context of their daily lives and what strategies and motivations they use to adhere 
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may contribute to not only supporting and sustaining good adherence, but also to keeping 
patients in care over time.   
 While there is an emerging collection of quantitative studies looking at the factors 
that create challenges for adherence in Africa (Byakika-Tusiime et al., 2005; Diabate et al., 
2007; Eholie et al., 2007; Hardon et al., 2007; Nachega et al., 2004; Orrell et al., 2003; 
Tadios et al., 2006; Weiser et al., 2003), few studies have explored the factors that facilitate 
adherence, and how the social and institutional context may contribute to optimal adherence. 
An exception to this gap in the literature is a study conducted in Kampala, Uganda, which 
considered factors that facilitated adherence through ten in-depth interviews with patients 
purchasing ART (Crane et al., 2006). The authors of that study found that near-perfect 
adherence was motivated by a belief that ART was responsible for keeping them healthy and 
by a desire to stay alive to look after the well-being of family members.  The authors 
concluded that these motivators outweighed the challenges patients faced securing funds to 
purchase ART in Kampala. 
Nearly all studies on factors that facilitate adherence, with the exception of the one in 
Kampala, have been conducted in North American settings, where there is a longer history of 
trying to understand and address adherence to ART. A published review of patient-reported 
barriers and facilitators to optimal ART adherence identified 23 qualitative studies conducted 
in North America (Mills, Nachega, Bangsberg et al., 2006). The facilitating factors that were 
reported consistently across the studies are detailed in Table 6.1.  Similar to other chronic 
illnesses, including diabetes, hypertension and tuberculosis, the factors that influence 
adherence to ART span across individual, inter-personal and institutional levels (Costa, 1996; 
S. A. Munro, Lewin, Smith et al., 2007; World Health Organization, 2003).    
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Table 6.1: Patient-reported factors that facilitated adherence to ART, as identified in 23 
qualitative studies in North America (Mills, Nachega, Bangsberg et al., 2006) 
Individual level factors 
• Having a sense of self-worth  
• Having a routine for taking ART 
• Belief in the efficacy of ART or expressing “faith” in treatment  
• Understanding the need for adherence  
• Accepting one’s HIV positive status  
• Using tools or strategies to remember to take pills  
• Seeing positive results when adhering to the ART regimen  
Inter-personal level factors 
• Having a strong support network  
• Being motivated to live for someone else, especially children  
Institutional level factors 
• Having a trusting relationship with health care providers  
 
Conceptualizing adherence as a function of multiple levels of influence is particularly 
important in an African context, where health behavior has long been understood as more 
than an individual choice. In ethnographic research on health-seeking behavior in Central 
Africa, Janzen and Arkinstall described “therapy management groups”, where sets of family 
members and friends mobilized around patients with the purpose of “sifting information, 
lending moral support, making decisions and arranging details of the therapeutic process” 
(Janzen et al., 1978, p. 4).  A similar pattern of care has been documented in Tanzania 
(Juntunen et al., 2002).  It is reasonable then to assume that one’s kinship system and 
community, as well as the nature of their interaction with the health care system, play 
important roles in determining adherence to therapy in Tanzania.        
Research on people’s experiences taking long-term medication may benefit from the 
application of behavioral theory as an organizing framework (World Health Organization, 
2001). The social cognitive theory (SCT) has been used as a theoretical lens for research and 
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intervention on adherence to ART (Diiorio et al., 2007; S. Munro, Lewin, Swart et al., 2007). 
The organizing concept of the SCT is reciprocal determinism, which asserts that personal 
factors, social factors and behavioral factors all interact to determine behavior.  According to 
the SCT, adherence is a function of one’s self efficacy to adhere, which is influenced, among 
other things, by positive reinforcements received to adhere, observational experiences of 
adherence, skills used to regulate adherence, and expectations of adherence (Baranowski et 
al., 2002). 
This article applied a theoretical framework of the SCT to explore how factors in the 
clinic setting, as well as in patients’ lives outside the clinic, enhanced their motivation and 
capacity to adhere to ART. It is the first study to document the perspectives of both patients 
and their HIV care providers on what facilitates optimal adherence to ART in a Tanzanian 
setting.  Understanding the motivations and mechanisms that patients are employing to 
adhere to their medications, and how these are reinforced in a health care setting, may 
provide important lessons for the expansion and sustainability of ART services in Tanzania 
and beyond.   
Study setting 
The study clinic was founded in 1954 by the Lutheran Church of Tanzania. It 
includes a 120-bed full-service hospital located on the outskirts of the Arusha metropolitan 
area and an outpatient clinic in the city center that houses the ART program.  As a non-
governmental health facility, the study clinic has been a mainstay of health services in 
Arusha, filling an important gap as government services have been affected by economic 
crises and structural adjustment measures for much of the last three decades (Lugalla, 2005). 
Its presence in Arusha is representative of the role that missionaries have played in providing 
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social services in the area since the beginning of the colonial period (Turshen, 1984).  The 
catchment area served by the study clinic includes over 500,000 people, representing the 
myriad of ethnic groups who either find their roots in or have migrated to urban Arusha.  
Residents of this area, like in the rest of Tanzania, utilize a combination of traditional healers 
and formal health facilities (Kayombo et al., 2007; Plummer et al., 2006).   
The city of Arusha is home to people who work in manufacturing and in the area’s 
tourism industry, as well as those who do petty business in Tanzania’s burgeoning informal 
economy, including such activities as selling used clothing or hawking household wares on 
the street corners (Tripp, 1997). A significant portion also relies on farming or the keeping of 
livestock for their economic livelihood. Residents of this area are generally impoverished. 
According to the 2004 Demographic Health Survey, only 17% of households in the Arusha 
region had electricity and only 4% had flush toilets. The majority (67%) of housing had 
floors made of mud or sand (Tanzanian National Bureau of Statistics et al., 2005).   
The first case of HIV in Tanzania was recorded in 1983, and since that time the 
disease has infiltrated the social landscape, taking on competing representations as a disease 
of migration, poverty, bad character, youth and modernity (Setel, 1999). The study clinic was 
among the first health care centers to respond to the epidemic in Arusha, with the 
establishment of its AIDS Control Program in 1986.  First oriented to providing HIV 
education and prevention, as well as support to orphans and affected families, the clinic 
began providing ART on a cost basis in 2003. In 2004, with the support of the United States’ 
President’s Emergency Plan for AIDS Relief (PEPFAR), the study clinic began offering 
ART and related HIV services free to all eligible patients. At the time of data collection, 
approximately 700 adults were receiving ART at the study clinic. 
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Patients may begin ART at the study clinic after being assessed for clinical readiness 
and receiving counseling about the medications.  Patients who have a positive HIV test result 
and a CD4 count of less than 200 or any symptoms representing a WHO clinical stage of IV 
qualify to start ART. Those who qualify are tested for TB and have appropriate blood tests 
done. The doctors discuss the results of these tests with patients and answer any questions 
they might have. In addition to clinical assessments, patients receive psychological support in 
individual meetings with trained counselors before initiating ART. The counselors reported 
that these pre-initiation sessions last an average of 20 minutes. The counselors provide 
information about the advantages of ART and what patients can expect, as well as potential 
side effects of the medication. They emphasize the life-long nature of ART and the 
importance of adherence, and they ask patients to make a commitment to using the 
medications as intended. Counselors encourage patients to bring a friend or family member 
to the clinic for the counseling sessions to ensure the patients have support for taking ART.  
It takes at least four visits (two weeks) from the time that patients first present to the clinic 
with an HIV positive test to the time that they are able to begin ART.  
The study clinic offers a peer support program for all ART patients, which it launched 
in 2005.  The program pairs voluntary adherence counselors (VACs) with ART initiates, 
matching them by their area of residence, whenever possible. VACs are HIV positive people 
who are trained to provide counseling to address problems patients might have taking their 
medications.  The VACs are supposed to support and follow up with their assigned patients 
for an indefinite period of time. At the time of the study, 15 VACs were serving at the study 
clinic, and the clinic was making plans to expand the program by training more peer 
supporters.  Patients meet with their VACs when they come for clinic appointments, and 
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VACs may also visit patients in their homes to understand their living situations, make 
necessary referrals, and provide supportive counseling to patients and their family members.   
After initiating ART, patients must make monthly follow-up visits to the clinic. 
During these appointments, patients have their weight assessed by a nurse, discuss their 
progress with a clinic counselor, and meet with a pharmacist to pick up their monthly refill 
and discuss any problems with the medications.  If patients have any clinical concerns, they 
may also meet with a physician.  Patients have their CD4 count measured every six months, 
providing the only routine clinical marker of their progress on ART.  
Methods 
This study was part of a larger mixed-methods investigation of adherence to ART.  
The data presented in this paper include in-depth interviews with six health care providers 
from the clinic and 36 patients currently taking ART. Health care providers were eligible to 
participate in the study if the majority of their working time was spent providing direct care 
to patients who were preparing to take or were taking ART, as determined by the hospital 
director. Eligible providers included physicians, nurses, counselors and pharmacists.  We 
introduced the study to health care providers at the clinic during a weekly meeting and then 
approached all eligible providers during working hours.   
Patients were eligible to participate in the study if they had been taking ART for at 
least one month at the study clinic, were at least 18 years of age, and could give informed 
consent.  We used maximum variation sampling with quotas (Patton et al., 2002) to ensure 
that we included both men and women who had been taking ART for various lengths of time 
(<6 months, 6-12 months, >12 months).  We set a minimum of at least four respondents for 
each combination of sex and time on ART, and continued recruitment and interviews until 
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we reached a saturation of themes.  Participants were recruited by two clinic counselors who 
routinely met with all patients coming to the clinic to pick up their monthly supply of ART.  
A member of the study team informed the recruited patients about the study and, if they were 
interested in participating, read them the informed consent form.  
Trained Tanzanian interviewers conducted the individual in-depth interviews with 
respondents in Kiswahili. Interviews took approximately 60 minutes and followed semi-
structured interview guides informed by the Social Cognitive Theory. The interview guide 
for health care providers included questions and probes about the services they provided to 
patients and their impressions of patients’ experiences taking ART.  The interview guide for 
patients included questions and probes about how ART fit into their daily routines, strategies 
used to adhere, motivations to adhere, barriers faced in adhering, and self-reported adherence 
over the past month. All patients and providers who participated in the interviews received 
5,000 Tanzanian Shillings (approximately four US dollars). 
The research staff audio-recorded the interviews, transcribed them into Kiswahili and 
translated them into English.  Transcription and translation occurred immediately after the 
interview. Interviews were reviewed in order to: 1) modify the interview guide to explore 
emerging themes; 2) give feedback to interviewers on their interviewing techniques; and 3) 
validate the quality and accuracy of translations. 
Translated, transcribed interviews were coded using Atlas.ti (Atlas ti, 1997), a 
software program that facilitates the organization and analysis of qualitative data. In the first 
phase of coding, deductive codes were drawn from the interview guide and research 
questions.  In the second phase, inductive codes were created and applied to identify 
additional themes, patterns and categories that emerged from the data (Patton et al., 2002). 
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The data were summarized through descriptive text-based summaries and data display 
matrices (Miles et al., 1994; Williamson et al., 2005).  Representative, verbatim quotes were 
selected to illustrate key findings. In selecting the two case studies that illustrated common 
characteristics in the context of patients’ lives, facts that were not relevant to the main theme 
were changed to protect respondents’ confidentiality. 
The study received ethical approval from the Institutional Review Board at the 
University of North Carolina’s School of Public Health, The Tanzanian Commission for 
Science and Technology and the National Institute for Medical Research in Tanzania.   
Results 
 The results are organized to first present the characteristics of the participants who 
took part in the study, followed by health care providers’ perspectives on the clinical context. 
The social context of taking ART in this setting is then discussed, providing two case studies 
as illustrations. Finally, the five factors that emerged as facilitating ART adherence in this 
sample of patients are presented, supplemented by findings of how providers reinforced these 
facilitating factors with patients. 
 
 Characteristics of study participants 
 The health care providers interviewed represented all of the eligible clinic staff and 
included two physicians, two nurses, one professional counselor and one pharmacist.  There 
were four male and two female providers, ranging in age from 35 to 49 (mean age 40).   
 The sample of patients included 19 females and 17 males.  The demographic 
characteristics of the 36 ART patients who participated in in-depth interviews are presented 
in Table 6.2. The average age of patients was 41.6 years, with male patients being older than  
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female patients (45.9 years vs. 37.7 years).  Only 14% 
of patients had received education  
beyond primary school and only 19% of 
patients had formal employment. Reporting no 
economic activity was more common for female 
patients than for male patients (57.9% of females had 
no economic activity vs. 11.8% of males).  
All patients were taking Triomune 
(manufactured by Cipla in Mumbai, India), a single pill 
containing stavudine, lamivudine and nevirapine. The 
pill is intended to be taken twice per day at a 12 hour 
interval.  Patients had been taking ART at the study 
clinic for an average of 9.8 months (range 1-23 
months), although this is not necessarily representative 
of the study clinic, as our sample was selected for 
representation by time on ART.  
Health care providers’ perspectives on the clinical 
context  
The comprehensive approach to services that the study clinic aimed to provide was 
reflected in the way that health care providers talked about their interactions with patients.  
Counseling was viewed as an integral part of on-going care and was considered the 
responsibility of all health care providers. As one provider explained, 
You need to understand a person. Therefore every person needs to be a 
counselor. Don’t say a patient is for [one health care worker or another].  A 
Table 6.2: Demographic 
characteristics of 36 patients who 
participated in in-depth interviews 
 
N
Age 
20-29 5
30-39 13
40-49 11
50 or older 7
 
Education 
No education 2
Some primary 3
Completed primary 26
Post-primary 5
 
Religion 
Christian 28
Muslim 8
 
Marital status 
Never married 5
Currently married 14
Separated/divorced 6
Widowed 11
 
Main economic activity 
Petty trading 9
Farming/ livestock 7
Formal employment  7
No economic activity 13
 
Time from home to clinic 
< 1 hour 26
> 1 hour 10
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patient is for everyone.  Everyone who faces the person should give advice 
properly. That is how we were told. 
 
 Providers emphasized that the content of the counseling was not just about the 
clinical manifestations of the drugs, but also about the social context of patients’ lives. Health 
care providers gave us the following examples of the types of questions they posed to 
patients during their meetings: “What are the things [you] encounter that make [you] despair, 
or things that encourage [you]? How do [you] face that?”; “How does the community see you 
now?”; “Do [you] get enough food? Does the food have all the nutrients the body needs?”; 
“How is home? Do people at home know that you are using medicine? Who usually helps 
you to use medicine?” Patients themselves confirmed having these types of conversations 
with providers. 
All of the health care providers with whom we spoke talked about a personal 
motivation to serve patients, which was in part grounded in the faith-based orientation of the 
clinic.  Although the clinic was not evangelical in its approach with patients, staff started 
each workday with a period of prayer and singing and closed all meetings with prayer. For at 
least two providers, their motivation to serve patients was related to the Christian ethic of the 
clinic, as one provider explained: 
We enjoy serving [patients] because this is a church center. Therefore when 
you serve the patient you see them like you are a part of their problem. So 
when you serve them you do it with all your heart. 
 
Social Context   
Patients described themselves as having some important characteristics that 
influenced their experiences living with HIV and taking ART. These characteristics, which 
were common across the majority of patients, shed some light on the life experiences of 
patients in this setting.  First, almost all patients reported economic insecurity, exacerbated in 
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many cases by long periods of HIV-related illnesses, losing a spouse, or both. Although no 
patients mentioned lack of food or money for transportation as a reason for non-adherence, 
both came up repeatedly as concerns for patients. When asked what additional support they 
would like from the clinic, the most common responses were food support and small loans to 
initiate business ventures.  Second, many patients expressed feeling depressed or hopeless 
after being diagnosed with HIV, often related to a belief that HIV was a death sentence.  For 
most patients, as their health improved with ART, so did their emotional state. Religion 
played an important role in regaining a sense of hope and purpose.  Third, almost all patients 
disclosed their HIV status very selectively in their social networks.  Patients decided whether 
to disclose based on the emotional closeness of a relationship, the perceived ability of a 
person to maintain their confidentiality, and how they thought a person would react to their 
HIV status.  Patients reported that when they were around people to whom they hadn’t 
disclosed their HIV status, they either hid their pills or told people the pills were for 
something other than HIV.  Lastly, most patients expressed a fear that people would treat 
them differently if they knew they were HIV positive, although less than half reported 
directly experiencing any stigma themselves. As one man said, “I was hearing that if you tell 
people about this problem, they will stop coming to my house or they will discriminate 
against me.”  
To illustrate for readers the experiences of patients taking ART in this setting, two 
case studies are presented. Each case highlights some of the important characteristics 
consistent across the 36 patients who participated in this study.  
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Case study 1: Bahati (pseudonym) 
Bahati is a 42 year old woman with a primary school education. She has never 
married but has had several long-term relationships, most recently with a married man. She 
lives with her three children in Arusha in a two-room mud house on a small plot of land next 
to her parents and brother. The house has electricity but no indoor toilet, and she must buy 
water from a public water pump 30 meters from the house. She keeps livestock as a means to 
support her children.  
Bahati came to the clinic after suffering from recurring illnesses and weight loss. “I 
was fat before! All the clothes I used to wear didn’t fit me. I was losing weight with no 
reason.” At the clinic she was advised to test for HIV. When she was diagnosed in August 
2006, she was very depressed. “The day I got my results was a difficult day. I didn’t sleep up 
to the next day. I mean, when I entered the room and my children called for me, I said they 
are calling me but I am going to die.” Soon after getting diagnosed Bahati became a “saved” 
Christian and found emotional support in religion that allowed her to accept her status and let 
go of her fear of death.  
Bahati started ART two months after being diagnosed, and had been taking the pills 
for three months at the time of the interview. She has experienced significant improvements 
in her health since starting ART. “I am now energetic unlike before I started taking this 
treatment. For sure they have helped me, and I expect more good changes.” She understands 
the life-long nature of the pills and the importance of adherence. She takes her pills at 7am 
and 7pm and has arranged her schedule to make sure she is home during those times. She 
said she has not missed a single pill since starting ART, and she worries even if she’s a few 
minutes late in taking her pills.  
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Bahati has shared her status only with one female friend. She does not want to tell 
other friends or family because of a fear of abandonment. Her ability to conceal her HIV 
status is made easier by the fact that she has experienced clinical success on ART and 
appears healthier. Bahati says about her choice not to disclose: “You can tell someone and 
create another problem. But now I am living happily because no one knows, they are still 
cooperating with me very well. But what if they knew? They will isolate me.” She doesn’t 
see her non-disclosure as impeding her ability to take her pills, because she says people don’t 
know that the pills she is taking are for HIV.   
When asked about taking ART for the rest of her life, Bahati responded that the 
medication has become part of her life. “I can’t stop because since I started to use the pills 
they help me. I can take care of my kids. I never asked for help; I do my work as usual; I’m 
strong; I have hope. So I do not worry and I must use my pills.” 
Case study 2: Japhet (pseudonym)   
Japhet, a 30 year old man, moved to Arusha from his village after completing primary 
school. He initially worked selling trinkets on the street and doing manual day labor (“pulling 
a wheelbarrow”) until he saved enough money to start a small shop selling basic food and 
household commodities. He married at the age of 19 and his wife gave birth to four children, 
one of whom died as an infant. At the time of the interview, his wife was pregnant with 
another child. He reported that he had several affairs with other women during times when he 
and his wife were not on good terms, and he believes that his infidelity was the source of his 
HIV infection. 
Japhet suffered from recurring illnesses for an extended time before getting tested for 
HIV. He talked about seeking treatment without getting a clear diagnosis: “They told me at 
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the hospital that it’s malaria. After five months, I got malaria again, then typhoid.  They gave 
me medicines but they were not telling me the problem.” As his health deteriorated, he 
couldn’t keep up his business and his capital dwindled. When his wife also began to get sick, 
he realized this may not be “normal illness” and decided to get an HIV test at a voluntary 
counseling and testing (VCT) center.  After getting his result, Japhet was distressed. “I was 
disappointed and thinking a lot of things, like my children are still young and I’m going to 
die.”  
Japhet was referred to the study clinic from the VCT center, and started ART less 
than a month after his positive diagnosis.  At the time of the interview, Japhet had been 
taking ART for five months. He had some nausea for the first few weeks, but then 
experienced great improvements in his health, which allowed him to go back to his normal 
activities: “Before I was getting up at 10am and felt tired by noon. But now I’m waking up at 
6am without forcing myself.” His daily routine is to wake up at 6am, open his shop, eat 
breakfast, brush his teeth and then take his pills. If he goes out of the house in the evening he 
takes his pills with him.  During the first month he missed a day of taking his ART because 
he didn’t return to the clinic in time for his refill. Now that he is familiar with the schedule of 
coming to the clinic for refills, he said he has not missed a single pill. However, Japhet 
expressed lack of knowledge about the life-long nature of ART (“I said to myself, ‘Will I use 
these for the rest of my life?’ I don’t know.”) and the importance of keeping to a regular 
timetable (“I usually take them at 7 in the morning and evening or 10 in the morning and 
evening. Tell me, is there any problem to do this?”).  Despite his lack of understanding of the 
life-long nature of ART and the ideal 12-hour dosing schedule, Japhet continues to take his 
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pills every morning and evening at the instructions of the doctor, and doesn’t plan to stop 
until the doctor gives him permission. 
Japhet’s wife is also HIV positive but according to Japhet she has not started ART. 
She blames her husband for infecting her with HIV. She refuses to have sex with him, which 
has led him to sleep on the floor of his shop, while his wife and children stay in their rented 
room. Other than his wife, only his brother knows that he is HIV positive. Although this 
brother isn’t able to support him financially, he goes to his brother when he has problems he 
needs to discuss. He hasn’t told other relatives because he does not think they will be 
supportive. If people see him taking his pills at the shop he tells them “I have chest 
problems.” 
Although Japhet’s health has improved considerably since starting ART, he still 
struggles with his economic situation and his relationship with his wife, as well as coming to 
terms with his HIV status: “Some of the time when I remember that I’m positive I get pain 
and think backwards [to the past]. But after a moment this disappears.” 
Self-reported adherence 
The case studies above highlight some of the potential barriers to ART adherence in 
this sample, including economic insecurity, depression, limited HIV disclosure, and high 
perceived stigma. Despite these potential barriers, the majority of patients had perfect 
adherence as measured by a single question of how many pills they had missed over the past 
month. The question was preceded by normalizing language (“It is not unusual that patients 
miss taking a pill for various reasons”). In response to this question, 32 of 36 respondents 
said they had not missed any pills.  Three patients said they had missed a single pill during 
the previous month (equivalent to 98% adherence), giving the following reasons: 
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• (Female, 30, 4 months on ART) Busy with an evening church event 
• (Female, 35, 10 months on ART) Fell asleep early and missed an evening pill 
• (Female, 53, 13 months on ART) Busy in the morning and forgot 
One respondent had intentionally stopped taking her pills for ten days (Female, 31, 18 
months on ART).  The reason she gave for discontinuing therapy was that she had malaria 
and was vomiting.  She said that when she explained this to the counselor at the next clinic 
appointment, she was advised to resume taking her pills and she did so. 
Reasons for overall excellent adherence 
Based on respondents’ narratives of their experiences taking ART, we identified five 
primary factors that facilitated adherence (Table 6.3). 
 
Table 6.3: Factors that facilitated ART adherence in the sample of 36 patients  
1.)   Patients experienced substantial improvements in their health by taking ART, 
increasing confidence in the medication and motivation to adhere. 
2.)   Patients were motivated to stay healthy and alive for the well-being of their family 
members, especially their children 
3.)   Patients made pill-taking part of their daily routine 
4.)   Patients received material and emotional support from others 
5.)   Patients trusted the advice to adhere given by service providers 
 
 1. Patients experienced substantial improvements in their health by taking ART, increasing 
confidence in the medications and motivation to adhere.  
Most patients had suffered severe and sustained illness before being diagnosed with 
HIV.  Twenty-five of the patients (71%) had a CD4 count of less than 200 at the time of 
diagnosis, requiring them to start ART immediately. As a result of having experienced long 
periods of illness, most patients had vivid illness narratives and an understanding of the 
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devastating impact of HIV on their bodies. These periods of illness contrasted sharply with 
improved health after starting ART, which increased confidence in the medications. 
I was sick for a long time, since 2002 up to 2006, and my main food was soda 
and pain killers….  It’s true that my life is good now. Since I started to take 
these drugs, I have no headache, no leg pains, and no body pains. (Male, 49, 6 
months on ART) 
 
Only about a third of respondents said they experienced side effects when starting 
ART (mostly abdominal symptoms), and all patients said that they had experienced 
improvements in their health on ART. Patients pointed to their increased weight, energy and 
the fact that they could return to work.  The marked improvement in health and resumption 
of normal activities attributable to ART created a strong motivation to continue taking the 
drugs. 
I have no such idea of stopping to take them for sure, because I was too much 
tortured before. I was sick for a very long time, I was just sleeping in bed. But 
now I am not. Therefore it’s not easy for me to stop them because they are the 
ones that made me better. (Female, 45, 17 months on ART) 
 
The perceived benefits of adhering were closely linked in patients’ minds to 
perceived negative consequences of not adhering.  When asked about the impact of missing 
pills or stopping ART altogether, most patients mentioned a fear that they would return to 
their previous condition or die. The association between adherence and avoidance of severe 
illness or death was evident even among patients who had been on ART for over a year and 
whose health had plateaued at a healthy state.  
I will die if my previous situation comes again. I am worried about it. 
Therefore I carry pills anywhere; even now I have them in my bag, because I 
may go out and sometimes be late, so I must take them. (Male 55, 14 months 
on ART) 
 
Health care providers said that they emphasized to patients the benefits of adhering to 
their ART for improving their health and prolonging their lives. A nurse said to a patient 
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whom she suspected of poor adherence, “I told him that these medicines are for prolonging 
your life, and if you stop you will go back to the condition you had before.” Another provider 
said that he sometimes held up examples of other patients or the VACs to illustrate the 
positive benefits of ART. “Sometimes we give them live examples, comparing a patient 
when they first started to their present condition. That helps them not to lose hope, to show 
them the medicine helps them.” 
2. Patients were motivated to stay healthy and alive for the well-being of their family 
members, particularly their children.   
Patients’ desire to improve their health and prolong their lives was as much a social 
motivation as an individual one. HIV affects people at the height of their reproductive cycle, 
and as a result the majority of respondents (31 of 35) had children under the age of 18.  
Patients’ experiences of near-death illnesses and their diagnosis with HIV, which many 
initially assumed was fatal, was often accompanied by a fear of not being able to support 
their families financially or leaving their children as orphans.  One man explained that his 
immediate reaction to his HIV diagnosis was asking, “Who will I leave my wife and kids 
with? I really wanted to see them start and finish their studies, the least I could do for them.” 
Taking ART offered patients an opportunity to return to work, support their families, and be 
around to take care of their children. Success on ART, achieved through adherence, allowed 
patients to resume or retain their roles in the lifecycles of their families. 
The desire to be around for their family’s well-being was a motivator to become 
healthy and therefore to adhere. Children as a motivator was expressed by more men (7) than 
women (2). As one man said, “I could never give up because I have kids.” The following 
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man had three children, ages 11 to 14. When we asked him how he felt about taking ART for 
the rest of his life, he replied: 
I use these drugs to prolong my life and to make sure my children go to school 
until they grow up. If you miss taking these drugs, you’re going to die. And 
you will leave the children as orphans. (Male, 36, 10 months on ART) 
 
 Another man was married to two women, one of whom died of HIV and the other 
who left him after he told her about his HIV status. He felt responsible for his 16 children, 
and decided to start ART in order to act on that responsibility:  
I have a large family of 16 children, and my father is in [the village], and he is 
very old now. So I decided to use the drugs for me to be able to take care of 
my family. (Male, 49, 6 months on ART) 
 
Two patients in our sample had only grown children. Those patients expressed shame about 
their HIV status and the burden they were placing on their children as a result of their illness. 
Although it was never explicitly mentioned, the desire to regain health in order to reduce the 
burden on adult children may also facilitate adherence. One man explained: 
It’s hard to seek support, crying for support… I do not want to be a burden to 
them, because I am supposed to help my children, not my children helping 
me. (Male, 55, 14 months on ART) 
 
Only one health care provider talked about drawing upon motivations for family 
obligations to support a patient’s adherence. She was advising a female patient who struggled 
to take her ART by saying to her, “Your weapon is medicine because your children are still 
young. If it were not for the medicine you wouldn’t be alive to support them.” 
3. Patients made pill-taking part of their daily routine. 
The requirement that ART be taken at the same time every morning and evening 
meant that patients had to adapt their routines to incorporate taking their pills. Almost all 
patients explained that they had very consistent and predictable schedules, with little 
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variation, which made it easier to incorporate pill-taking. The following woman explained 
how taking ART at 10AM and 10PM fit into her daily routine. 
I arranged to take them at 10AM. I can just wake up and do my work. I do the 
dishes, mop, take a shower, then at about 9:45 I take my tea. I look at my 
watch and at 10am I take my medicines. If I have somewhere to go, I go, and 
when I come back, I prepare food, prepare my children, they eat and take time 
watching sports. And my husband and I are just resting after we finish 
fetching water, because we normally fetch water at night. So after fetching 
water, the children have already eaten, and I sit down and eat. I just look at the 
time while eating. And when it reaches 10PM I stop eating and take my drugs. 
After that I take a short rest and I go to sleep. (Female, 30, 6 months on ART) 
 
Patients talked about their efforts to keep regular schedules and prioritize the time to 
take their pills, as explained by the following woman. 
Using them becomes like a normal timetable, like that of a working schedule. 
For example if you have a cow, when you wake up you know at what time 
you’re going to feed that animal, and this is the same with my drugs. I have 
the same timetable. I can’t do my work without taking the drugs first, then 
after I take my drugs then I am free to work. (Female, 40, 4 months on ART) 
 
When we asked patients how they remembered to take their pills on time, many 
simply said that it’s “hard to forget” or “always on my mind.” One patient said “I take it as 
food, which you have to eat every day.” The dominance of ART in patients’ daily thoughts 
and activities seemed to be related to a constant memory of their previous condition and the 
life-saving nature of their ART.  One patient compared his consciousness about ART to a 
soldier who must always be aware of where his weapons are located.   
You know we are like soldiers who are taking care of the weapons and they’re 
not supposed to leave it anywhere. So I always take my pills when I leave the 
house. (Male, 49, 4 months on ART) 
 
The primary disruption in patients’ schedules was traveling out of town for work or to 
visit family, or being busy and out of the house for long hours.  When asked about this, 
respondents said that they prioritized pill taking and had strategies for carrying their pills, 
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water and food.  Patients who traveled out of town usually said that their pills were the first – 
and most important – thing they packed when getting ready for a trip. 
I can’t forget - it’s all the time in my mind. When I have a trip I’d better pack 
my pills and forget my clothes. And I go with enough water to last every day. 
(Male, 31, 13 months on ART) 
 
Patients also talked about strategies they used to remember to take their pills. Four 
respondents said they set alarms on watches or cell phones (cell phones were common in this 
setting).  More often, however, patients anchored the time of taking their pills with other 
regular activities, such as meal or tea times, brushing their teeth, prayer, or radio or television 
programs.  
A doctor we spoke with told us how he advised patients about different strategies they 
might use to remember to take their ART. 
We normally advise them to use the alarm clock, so they set it in the morning 
at 7, or whatever time they decided to take the medication. So when the time 
comes the clock will ring. We also say that they should put the medication 
bottle close to where they put their toothbrush so when they go to brush their 
teeth they know that this is time for their medicine, so they take the medicine 
and they brush their teeth. So then they remember. Also when they go to 
sleep, if there is a place where they normally put something important they 
should put the medication at the same place; therefore when they go around 
they find their medicine right there.  
 
4. Patients received material and emotional support from others to help them take their ART. 
Social support facilitated adherence through direct reminders to take pills, material 
support of food and money, and emotional encouragement. As mentioned earlier, most 
patients disclosed their HIV status selectively within their social networks.  Twenty-nine told 
a select group of people they were HIV positive, six told everyone in their social network, 
including family, friends and neighbors (although one man in this group said he did not want 
his elderly mother to know and one woman was withholding the information from her 
 86 
 
landlord), and only one person told no one.  Respondents made decisions about whether or 
not to disclose to people in their lives based on perceptions of support they would receive 
from each person.  As this woman shared: “Some people when you tell them they will feel 
you are dying now. It seems as you shock them. They are not happy and you are not happy 
either. Therefore it is not in all situations that you are open.”  Disclosure was often seen as a 
strategy to garner support for living with HIV and taking ART. 
The most direct way that patients received support to adhere was through explicit 
reminders to take their pills. Fourteen respondents said they had someone who provided these 
reminders. When the patient’s spouse or partner was also taking ART (five respondents), 
they usually reminded each other. As one man said of his wife, “She is the one who reminds 
me about the pills and gives me food. We help each other a lot.”  Ten respondents said that 
their children reminded them of the time to take their pills, even if they hadn’t directly 
disclosed their HIV status to their children. One woman, whose own child was only three, 
had engaged other children in the neighborhood to remind her: “At the place I am living there 
are children. So I told those children to remind me when it reaches 8:00. I told them to come 
to tell me wherever I am.”  Other respondents had family members call them or visit them to 
remind them to take their pills. 
Most respondents (24 of 36) received material support, primarily from family 
members, in the form of food and money.  Respondents gave the impression that the 
supporters gave material support because of the general hardships the respondents were 
facing in their lives, not explicitly because of their HIV status or to help with taking their 
ART.  Nevertheless, respondents spoke about the importance of this type of support for 
taking ART, as this respondent related: “If you want to enjoy taking these pills and have 
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them help you, you must have some food. If you have some food, then there is no other 
problem.” 
Although our questions about support first elicited responses about reminders and 
material support, probing by interviewers also revealed that patients received important 
emotional support that made it easier for them to take their pills. Almost all respondents (29 
of 36) talked about receiving some emotional support, often related to general 
encouragement or to ‘normalizing’ HIV and giving examples of other people with HIV who 
were living productive lives. One female patient who was taken in by her brother and his 
family after she became ill said that her brother and sister-in-law not only reminded her to 
take her pills, but also encouraged her to live positively with HIV, which seemed to increase 
her motivation to take her ART properly. 
They really help me, give me advice. Even encourage me, because sometimes 
I feel heartbroken. To some extent they help to give me courage, so that I can 
see it as a normal thing. (Female, 30, 4 months on ART) 
 
While the vast majority of patients said it was family members who provided the 
most important support to them, two patients pointed to friends in this role. One woman 
explained how her in-laws took all her property after her husband died of HIV and insisted 
that she come live with them in the village. When she decided to stay in town, she was given 
support by a close friend of her deceased husband. The friend rented her a room and put her 
in touch with a church that could provide her with food support. He bought her a mobile 
phone so that she could set an alarm to remind her of the time to take her pills and so that he 
could call her to check that she had taken them. 
The voluntary adherence counselors (VACs) at the clinic also played an important 
role in providing support to patients.  Almost all respondents (33 of 36) said they had a VAC 
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assigned to them. Of those, 26 said that their VACs gave them important information 
relevant to adherence, and 14 said that their VACs gave them some form of emotional 
support. The fact that the VACs were also HIV positive made the information and emotional 
connection even more salient. As one woman said, “When you talk with a person with the 
same problem as you it’s easy to understand each other well.”  The importance of emotional 
support provided by the lived experiences of their HIV positive peers was expressed by the 
following respondent.  
She told me that she was so sick (before), only sleeping at home…. She told 
me she was suffering, until people were afraid. But today they forgot that she 
was like that. She gave me hope because of how she changed and improved.  
She gave me hope so that I’m serious about using ART. (Female, 40, 4 
months on ART) 
 
 Health care workers spoke about their efforts to engage family members or friends in 
patients’ care. They did this by encouraging patients to bring their supporters to clinic 
appointments, counseling the supporters when they attended, and having VACs follow up 
with family members in the home. This doctor talked about the benefits of engaging the 
patient’s support system. 
It is a benefit, especially for adherence to the medication. It is believed that if 
they involve a second person, it reduces stigma first and then it improves 
adherence to the medication. And these people can also assist them to take 
medication, like telling them that they forgot this medication today. Or 
sometimes the patient asks the relative to come and collect the medication, in 
case they can’t come themselves.   
 
5. Patients trusted the advice of service providers 
Lastly, patients expressed an absolute trust in the advice of service providers at the 
study clinic, which motivated them to adhere. Patients consistently said that counselors, 
doctors and VACs all emphasized the importance of adherence in their interactions.  Patients 
accepted this advice without reservation, in no case questioning the expertise or advice of 
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these providers.  Having trust in the advice of service providers allowed patients to overcome 
any lack of knowledge about the impact or long-term nature of ART. When we asked the 
following patient if he believed that the ART might cure him completely of HIV, he said he 
wasn’t sure. When we followed up to ask if he would ever stop taking his ART, he told us 
that he would not stop until instructed to do so by the doctor. 
I will not stop, even if there are side effects, because I was told to use it. If I 
stop for some reason, it will be bad. If the doctor who gave me the pills tells 
me that I’m supposed to stop, I will stop, but apart from that I will use it, even 
if there are side effects. (Male, 49, 4 months on ART) 
 
Overall, patients felt very positively about the services they received at the study 
clinic, particularly comparing the study clinic to other clinical settings they had experienced. 
The things they appreciated about the clinic were the information they received on taking 
ART and the openness of staff to addressing their problems. One patient told us: 
There are good services here compared to other clinics, where they don’t want 
to listen to patients.  There, when you talk to a doctor they already call in the 
next person. So these services here are good. Let them keep it up. (Male, 49 
years old, 3 months on ART) 
 
Trusting health care providers may in part have to do with the relationships that 
providers tried to build with patients. One provider explained how he related to patients: “I 
make jokes sometimes to make patients feel comfortable, so you can explore their insights 
and they can tell you how they feel…. You feel free to chat with patients and they feel free to 
chat with you.”  Another provider recognized the importance of building such relationships 
when she said, “It is important that they trust you a lot. So we are trying to build good 
relationships between the patients and the staff.” 
Synthesis of facilitating factors  
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The factors that emerged as facilitating adherence to ART in this setting resonated 
with the constructs of the Social Cognitive Theory (Baranowski et al., 2002).  Factors at the 
individual, inter-personal and institutional levels interacted to positively influence adherence.  
Patients drew upon their own personal experiences (being ill and recovering with ART) as 
well as role models of the VACs to develop expectations of positive adherence outcomes that 
motivated their behavior.  The desire to support their families placed added value on the 
outcomes of renewed health and sustained life.  Emotional support in the form of 
“normalizing” HIV increased motivation to adhere. Patients exhibited self regulation in 
developing strategies to integrate adherence in their daily routines, which was supported by 
reminders from friends and family.  Health care provider reinforced patients’ inherent 
motivations and skills.  Together, these factors appeared to positively influence patients’ self 
efficacy to adhere to ART, despite the presence of potential barriers (Figure 6.1).  
 
Observational learning 
through role models 
Expectation of 
improved health 
Value placed on 
improved health 
Social support 
Self regulation 
Motivation to 
adhere 
Skills to 
adhere 
Self efficacy 
to adhere 
despite 
barriers 
Reinforcements from health care providers
ADHERENCE
Reinforcements from health care providers
Figure 6.1: Explanatory model of factors that facilitated ART adherence in this sample 
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Limitations of the study 
The results of this study must be interpreted in light of the study’s limitations. First, 
the high adherence we found in this setting must be interpreted cautiously because of the 
possibility of self-reporting bias (Bell et al., 2007). Self-reported measurements of adherence 
likely over-estimate adherence due to recall bias and social desirability (Arnsten et al., 2001; 
M. A. Chesney, Morin et al., 2000; Liu et al., 2001), but self-reported adherence 
measurements have nevertheless shown to be associated with other, more ‘objective’ 
measurements of adherence (Arnsten et al., 2001; Oyugi et al., 2004) and to be associated 
with viral load (Arnsten et al., 2001; Duong et al., 2001; Fairley et al., 2005; Fletcher et al., 
2005; Liu et al., 2001).  Second, the themes reported in this paper are limited to the issues 
that individual respondents chose to discuss during the interviews. While the interview guide 
included broad questions and probes for follow-up, the depth of discussion on the topics was 
not standard across the interviews.  The proportion of patients reporting various factors must 
be interpreted as descriptive only, bearing in mind that not all patients were asked the same 
questions in the exact same way.  Additionally, no observations were conducted of patient-
provider interactions, requiring us to rely solely on self report, which is subject to social 
desirability bias.  Finally, as applies to any qualitative study, the results are not meant to be 
statistically generalizable to a larger population, but to illuminate aspects of experience and 
context that may be shared by others.  
Discussion 
This qualitative inquiry suggests that the contexts of patients’ lives present potential 
barriers to ART adherence that have been observed in other studies. These include poverty, 
emotional distress, low rates of HIV disclosure, and high levels of perceived HIV-associated 
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stigma (Fogarty et al., 2002; Hardon et al., 2007; Mills, Nachega, Bangsberg et al., 2006; 
Sankar et al., 2006; Vervoort et al., 2007).  Despite the potential barriers, self-reported 
adherence was excellent for this sample, with 32 of 36 patients reporting perfect adherence 
over the past month and only one patient reporting less than 95% adherence.  
Similar to other studies (Abel et al., 2003; Adam et al., 2003; C. Golin, Isasi et al., 
2002; Misener et al., 1998; Murphy et al., 2000; Remien et al., 2003), a primary factor that 
facilitated adherence in our sample was a belief in the efficacy of the medications to improve 
health and prolong life.  This belief came from patients’ subjective experiences transitioning 
from debilitating illnesses before starting ART to improved health after initiating therapy.  
Recalling their previous illness served as a strong motivator to adhere to their medication.  
The clinic environment, including having the VACs as role models and the counseling 
provided by health care providers, likely reinforced the benefits of ART for patients and 
enhanced their motivation to adhere.  
A desire to be alive to support their families also motivated patients to adhere, as has 
been documented in other studies (C. Golin, Isasi et al., 2002; Murphy et al., 2003; Remien et 
al., 2003; Richter et al., 2002; Sankar et al., 2002; Stone et al., 1998; S. A. Wood et al., 
2004). However, while most of these other studies have documented patients’ desire to be 
around to “see their children grow up,” respondents in this study spoke more about their 
responsibility for the economic well-being of their children, particularly to ensure that their 
children get an education.  In addition, while most North American studies have documented 
family as a facilitating factor of adherence primarily among women (Misener et al., 1998; 
Remien et al., 2003; Richter et al., 2002; S. A. Wood et al., 2004), in this study it was a more 
salient theme among male patients.  This must be understood within the context of the 
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patrilineal system of Northern Tanzania, where men are often the key decision makers in 
areas of child rearing and care that require significant outlays of funds, including post-
primary education, vocational training, or semi-formal apprenticeships that children might 
receive to establish their own economic independence.  Men feel an obligation to meet these 
costs and see their children ‘established’ in this way (Personal communication with Philip 
Setel, 2007). 
 Patients reported consistent and predictable daily routines, which made it easier for 
them to integrate pill-taking into their daily lives. North American studies have documented 
unstable lives, shifting routines, and the fact that “every day is different” as one of the 
primary challenges to taking ART on schedule (Adam et al., 2003; C. Golin, Isasi et al., 
2002; Murphy et al., 2000; Ryan et al., 2003).  Because patients in this sample had consistent 
routines, they could anchor their pill-taking to daily events like morning tea, brushing their 
teeth, or bedtime.  Having a simple medication regimen (one pill twice a day) may also have 
contributed to more ease in integrating pill-taking into their daily routines. Regimens that 
have fewer pills and doses have been associated with better adherence to ART and other 
chronic therapies (Bangalore et al., 2007; Diabate et al., 2007; Mills, Nachega, Bangsberg et 
al., 2006; Orrell et al., 2003).  The greatest disruption to daily routines in this sample was 
travel, but patients who traveled talked about strategies for carrying their pills with them and 
taking their pills while out of the house.  The self-reported consistency of patients’ routines 
would benefit from validation by ethnographic observations, which might reveal changes 
over time and across seasons that were not reported in the interviews.   
The positive influence of social support on adherence has been documented in both 
qualitative (Adam et al., 2003; Campero et al., 2007; Klitzman et al., 2004; Malcolm et al., 
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2003; Remien et al., 2003; Sankar et al., 2002; Weiss et al., 2006) and quantitative studies 
(Diabate et al., 2007; Gonzalez et al., 2004; Gordillo et al., 1999; Murphy et al., 2004; 
Vyavaharkar et al., 2007).  Social support arose as an important facilitating factor among this 
sample, taking the form of direct reminders, financial help and emotional support. While 
reminders and emotional support have been documented as facilitating adherence in the 
qualitative studies cited above, the expressed importance of financial help was unique to this 
setting.  This is likely related to the poverty in our sample, the lack of public assistance, and 
the potential barriers to adherence of hunger and transportation costs, which have been 
documented in other African settings (Hardon et al., 2007).   
The support that people received to cope with their HIV infection appeared to be 
more on the basis of individual, one-on-one support, rather than a group of people mobilizing 
to support the patient, as has been found in response to acute illnesses (Janzen et al., 1978). 
This may be due in part to the nature of disclosure (and non-disclosure) of HIV, as well as 
the fact that respondents were discussing the sustained, rather than illness-focused, support 
that they received. Health care providers in the study clinic recognized the influence of 
patients’ support networks on adherence and encouraged patients to involve their supporters 
in routine care. The VACs at the clinic also provided information and emotional support that 
particularly resonated because of the VACs’ personal experience living with HIV. 
Finally, patients’ trust in the advice of health care providers and VACs facilitated 
adherence in this sample. Patients perceived these providers as referent authorities whose 
advice they should follow without question, and the advice they were being provided was to 
adhere to their medication. The influence of patient-provider relationships is consistent with 
findings from other qualitative studies (Abel et al., 2003; C. Golin, Isasi et al., 2002; 
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Malcolm et al., 2003; Murphy et al., 2003; Murphy et al., 2000; Remien et al., 2003; Roberts, 
2002; Sankar et al., 2002).  Providers in the study clinic recognized the importance of 
building trusting relationships with patients, and did so by having thoughtful conversations 
with patients and attempting to reduce the gap between provider and patient. 
The clinical environment itself likely had a positive influence on adherence in this 
setting.  The health care providers we spoke with all expressed a personal motivation to do 
their work, grounded in an ethic of service that seemed in part influenced by the faith-based 
orientation of the clinic.  The fact that the study clinic aimed to provide a continuum of care 
to patients by offering a range of services for people living with and affected by HIV/AIDS 
reflected a broader commitment to seeing patients as whole people with needs and influences 
outside of the clinic setting. Strong patient-provider relationships are essential components of 
a chronic care model that can support and sustain adherence over time (Swartz et al., 2002; 
World Health Organization, 2002a). Although this study was not a formal evaluation of the 
VAC program, the findings do suggest there was a positive influence of this peer support 
program for people taking ART.  The HIV positive peer supporters provided role models for 
how HIV positive individuals may return to good health by making a commitment to taking 
ART.  Counseling that these peers provided to patients based on their own personal 
experience was particularly salient.  In addition, home visits by these peers have the potential 
to further engage the patients’ natural support systems. A future direction of research is to 
examine the VACs program for its impact on patients’ adherence. 
The findings presented in this paper highlight the importance of, first, understanding 
the motivators and strategies that patients are employing to adhere and, second, integrating 
that understanding into the health care system so that providers can recognize and reinforce 
 96 
 
patients’ inherent motivators and strategies. The implication for practice is that ART 
programs and their targeted interventions must address not only each of the levels of 
influence, but also find ways to ensure connections and reinforcements among these levels.  
Comprehensive ART programs that make these connections and are grounded in the unique 
social context of their settings have shown success in promoting and sustaining adherence 
(Koenig et al., 2004; Mukherjee et al., 2006; Weidle et al., 2006).  
Future research on this topic may benefit from different methodological approaches 
using qualitative methods. Observations of patient-provider interactions would provide more 
information about the nature of communication and would validate self-reported findings 
from providers.  To understand how patients’ support systems influence adherence, studies 
should seek the perspectives not only of patients, but also of other actors in patients’ lives 
essential to sustaining adherence. Finally, because adherence is a dynamic process that may 
change over time, multiple contacts with respondents may be more useful than single 
interviews (Conrad, 1990). 
Despite the limitations faced in the study, this is the first qualitative study on the 
factors that facilitate patients’ adherence to ART in Tanzania, and it therefore increases our 
understanding of why adherence might be high in a low-resource setting, despite the presence 
of potential barriers. 
  
VII. CONCLUSIONS 
Summary of findings 
Guided by a theory-informed conceptual framework, this study set out to understand 
the factors that influenced patients’ adherence to antiretroviral therapy in a single clinic in 
Tanzania.  The study was undertaken with four aims: to assess the level of adherence in a 
sample receiving free ART in Tanzania; to identify significant correlates of ART adherence; 
to explore how the social environment of patients’ lives supports ART adherence; and to 
assess the role of mediating and moderating factors in the relationship between social support 
and adherence.  The qualitative and quantitative methods used to address these aims 
complemented each other and produced a richer understanding of adherence in this setting. 
Aim one: Assess the level of adherence in a sample receiving free ART in Tanzania  
The study identified high levels of adherence in this sample.  As reported in the first 
manuscript, over 94% of patients in the survey interviews reported optimal adherence in both 
the previous four days and previous month.  The finding of high adherence is encouraging, as 
it represents better adherence than has been measured by self report in other African settings 
(Byakika-Tusiime et al., 2005; Diabate et al., 2007; Eholie et al., 2007; Nachega et al., 2004; 
Weiser et al., 2003).  The high adherence may in part be explained by characteristics of the 
clinical services. All patients in the study were receiving ART and related laboratory and 
treatment services at no cost, removing a financial barrier that has been observed as an 
adherence barrier in other settings (Byakika-Tusiime et al., 2005; Eholie et al., 2007; Weiser 
et al., 2003). Additionally, almost all patients in the study were taking very simple ART 
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regimens that involved one pill twice a day, which has not been the case for previous studies 
on adherence in Africa. An increasing number of doses and pills have consistently been 
associated with poorer adherence (Ammassari, Trotta et al., 2002; M. Chesney, 2003; 
Diabate et al., 2007; Laniece et al., 2003; Orrell et al., 2003). 
Aim two: Identify significant correlates of ART adherence 
While adherence was high in this setting, not all patients managed to adhere to their 
medication. Three factors emerged that differentiated those who achieved adequate 
adherence from those who did not achieve adequate adherence. Both patients who were 
younger (19-30 years) and older (over 50 years) were at greater risk for poor adherence, 
compared with patients ages 31-49.  Patients who had ever missed a clinic appointment were 
more likely to report poor adherence.  In addition, patients who had a lower assessment of the 
quality of their interaction with providers reported poorer adherence. 
Aim three:  Explore how the social environment of patients’ lives supports ART adherence 
The in-depth interviews, presented in the second manuscript, helped to explain the 
factors that facilitated adherence in this setting.  The facilitating factors represented 
influences at the individual, inter-personal and institutional levels.  The most important 
facilitator appeared to be patients’ belief in the efficacy of the medication based on their 
personal experience. All patients were able to contrast their poor health prior to starting ART 
with their improved health after starting the medication, which increased their motivation to 
adhere. Patients believed that if they did not take their drugs properly, they would likely face 
illness or death, and they wanted to avoid this in order to be around to support their families. 
Their families in turn provided them with reminders, material assistance and emotional 
support that helped their adherence.  Patients had very predictable and consistent routines 
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that allowed them to easily integrate a schedule of taking their medication regularly and on 
time, and they developed skills and strategies to remember to take their pills properly. 
Finally, patients trusted the advice of their providers, and providers worked to build strong 
and trusting relationships with patients.  
As this was not a comparative study, it is impossible to definitively attribute the high 
adherence in this setting with the characteristics unique to the study clinic.  However, the 
interviews with patients and providers give reason to believe that the nature of the setting had 
some positive influence on adherence. The mission of the clinic to “serve, treat and minister 
to the whole person, in body, mind and spirit” appeared to contribute to clinic staff respecting 
and responding to the patients’ social context. Counseling was a central component of the 
ART services and providers encouraged patients to bring their family members with them to 
appointments. Clinic staff expressed a motivation to serve patients, grounded in the faith-
based orientation of the institution, which might have resulted in better quality of care 
compared with their counterparts at large government-run hospitals.  
The data from the second manuscript underscored the contribution of the social 
cognitive theory and the construct of social support for understanding adherence in this 
setting.  The in-depth interviews highlighted how patients’ expectations of adherence 
outcomes, the values placed on those expectations, observational learning from role models, 
social support and behavioral capability influenced patients’ motivations and skills to adhere 
to their ART.  Theses motivations and skills, reinforced by health care providers, increased 
patients’ self efficacy to adhere and allowed them to overcome potential barriers to take their 
medication as instructed. 
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Aim 4: To assess the role of mediating and moderating factors in the relationship between 
social support and adherence 
 Social support was not a significant predictor of adherence in the survey, making it 
impossible to address this aim statistically. The lack of association may be due to inadequate 
power in our sample, or it may be an appropriate reflection that those who achieved 
adherence in this setting did not necessarily have higher levels of perceived social support 
from those who did not achieve adherence.  
The qualitative data, on the other hand, points to the importance of social support in 
facilitating good adherence.  Patients talked about three forms of support they received from 
family members: reminders to make medication, emotional support that helped to 
‘normalize’ HIV, and material support in the form of food and money.  Reminders that 
patients got from others contributed to their adherence skill set and directly helped them 
remember to take their medication on time.  Emotional support increased patients’ 
motivation to adhere by providing an expectation that they could achieve good health and by 
placing greater value on good health. Material support assisted patients to overcome direct 
barriers of lack of food and transportation fees, which may have otherwise hindered 
adherence.  In this way, the qualitative data suggests that social support influences adherence 
by increasing patients’ skills and motivations to adhere and also by directly impacting their 
self efficacy to adhere, despite potential barriers. 
Study limitations 
 The study was limited by several factors. In the survey, adherence may have been 
over-estimated due to social desirability bias in patients’ self report.  Additionally, the 
recruitment strategy missed individuals who have dropped out of the ART program or who 
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did not come to clinic during the recruitment period, which may have introduced an over-
estimation of adherence.  The small number of cases who reported poor adherence limited 
the number of predictor variables that could be included in the final model and precluded the 
investigation of interactions among the predictor variables.   
  The in-depth interviews were similarly subject to social desirability bias.  Single 
contacts with respondents meant that the interviewers had limited time to build rapport and 
probe for inconsistencies in self reports.  No observations were conducted of patient-provider 
interactions to confirm what patients and providers reported. The semi-structured nature of 
the interview guide meant that the depth of discussion on topics was not consistent across 
respondents, making the presentation of proportions of respondents reporting various factors 
descriptive only. 
 In both the survey and in-depth interviews, social desirability bias was minimized to 
the extent possible by using normalizing language (e.g., “It is normal for patients to not take 
their pills as they are supposed to”) and by training interviews on strategies to gain 
respondents’ trust and elicit honest responses.  Limitations that were specific to the methods 
– such as inadequate power to detect differences in the survey and lack of consistency in the 
qualitative interviews – were reduced by the use of complementary methods. The in-depth 
interviews provided a more detailed and nuanced exploration of the factors that influenced 
adherence than was possible in the survey interviews, while the survey data allowed us to 
make more generalizable conclusions about the data than was possible from the in-depth 
interviews. 
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Implications for research and practice 
 The findings reported here have implications for research and practice. First, the 
findings highlighted several characteristics of the clinic setting that may have attributed to 
the excellent adherence in this sample. Studies are needed that compare multiple sites and 
ART program models, in order to identify the characteristics that best support patients’ 
adherence.  This may include comparisons of different size clinics and faith-based versus 
government facilities. The VACs program may have also contributed to the high adherence 
in this sample, and deserves evaluation as an intervention model.      
The influence of patient-provider interactions on adherence emphasizes the 
importance of training health care providers to ensure a patient-centered approach.  As ART 
programs expand to include more patients, it will be important to ensure that providers have 
enough time with patients to develop and sustain trusting relationships.  Peer educators may 
help to fill the gap where medical professionals are overstretched or unavailable. Additional 
research is needed to determine what aspects of interactions with providers patients most 
value and have the strongest influence on adherence. 
 The association between age and adherence deserves further attention. Both younger 
and older patients may need additional support when starting ART.  Further research on the 
challenges that both of these groups face may help develop tailored counseling messages and 
support mechanisms. The experience of older people living with HIV is particularly 
neglected and deserves further attention. 
 Although adherence was high in this setting, there is nevertheless need to develop 
interventions to sustain and support adherence, particularly as access to ART expands.  
Models for adherence interventions in developing countries often rely on intensive individual 
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counseling, telephone follow up, or mechanisms such as pagers or financial incentives (Cote 
et al., 2005; M. Haddad et al., 2000; Simoni et al., 2003).  In developing country settings, 
where limited financial and human resources do not permit such interventions, a community-
based approach that mobilizes social support is often used to promote patients’ adherence 
(Behforouz et al., 2004; Coetzee et al., 2004; Koenig et al., 2004; MSF, 2004).  The findings 
of this dissertation study suggest that an approach that mobilizes social support would be 
valuable in this setting. At the same time, our findings indicate that health care providers 
need to be trained and mobilized to support patients’ adherence.  Providers’ willingness and 
ability to appropriately communicate with patients and to identify and support their 
motivations and skills in taking ART are essential for supporting and sustaining patients’ 
adherence over time. 
Pilot intervention 
 The findings from this research have already been leveraged into a small study to 
develop and pilot test an intervention for ART initiates and their treatment supporters at the 
study clinic. A group intervention was chosen as the delivery mode because we found that 
social support helped patients to live positively with HIV and adhere to their medication, but 
at the same time patients feared disclosing in their social networks due to perceived stigma.  
Informal conversations with the research team and clinic staff suggested that a group seminar 
for patients and their supporters may not only deliver important information, but it may also 
help to normalize HIV, leading to increased disclosure and support. During the home visits, 
patients were asked about their interest and willingness to participate in a seminar with a 
treatment supporter. All patients responded that they would come and felt they would benefit 
from such a seminar. 
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The content of the half-day seminar was informed by the findings of the dissertation, 
a review of other adherence interventions, and ten focus group discussions that we conducted 
with patients, their treatment supporters and health care providers.  Because the dissertation 
work pointed to the saliency of the Social Cognitive Theory, we used constructs from the 
SCT to inform the intervention.  The application of these constructs included: introducing 
role models by having HIV positive facilitators lead the seminar; practicing emotional 
coping, behavioral capability and self control through appropriate role plays; increasing self 
efficacy by anticipating barriers to adherence and brainstorming challenges to overcome 
those barriers; and making patients’ social environments more conducive to taking ART by 
equipping patients’ self-identified supporters with knowledge and skill to provide appropriate 
support. 
We recruited 38 patients to participate in the pilot testing of the seminar, and 29 
(76%) attended. Of those, 12 (41%) brought treatment supporters, including seven relatives 
and five friends. Feedback on the seminar was positive. When asked to rate the helpfulness 
of the seminar on a scale of one to five, 24 patients (83%) and eight supporters (67%) gave 
the seminar a five as “very helpful”. Focus group discussions with patients and supporters in 
the week following the seminar elicited feedback on ways to improve the intervention. While 
the results of the pilot are still being analyzed, the preliminary findings demonstrate that most 
patients were willing and able to attend the seminar and almost half brought treatment 
supporters. In the evaluation of the pilot, participants rated the sessions favorably, providing 
evidence that this may be a useful model for improving quality of life and supporting 
adherence to ART at this site.  
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Future topics for data analysis 
This dissertation study has only begun to touch on the many available research topics 
in the data collected. Below are several additional research areas outside of the issue of 
adherence that can be undertaken with the data at hand.     
1. Social support from perspectives of ART patients and their supporters: Social support 
emerged as an important facilitator of adherence in the in-depth interviews.  A 
qualitative analysis of the patient interviews, paired with their supporters, will 
provide a better understanding of the nature of social support in this sample and how 
ART programs and interventions may maximize social support. 
2. Role of religion: Religion emerged as prominent in the in-depth interviews with 
patients. Patients talked about finding support and hope in their faith, but said they 
rarely heard messages about living with HIV from their mosques and congregations 
and were reluctant to disclose in their religious communities for fear of stigma.  
These findings may identify missed opportunities for religious organizations to 
support people living with HIV. 
3. Patterns of HIV disclosure: It is important to understand HIV disclosure in order to 
inform HIV prevention efforts and to ensure that HIV positive people access and are 
retained in care (R. King et al., 2007). Data from the survey and in-depth interviews 
with patients can be combined to shed light on the groups of people to whom people 
are disclosing (e.g., brothers, sisters, neighbors, church leaders), the order in which 
they disclosed, reasons for disclosing and not disclosing, and experiences of ‘indirect 
disclosure’.   
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4. Measurement of perceived stigma: The stigma scale that was developed for the survey 
was adapted from measurement work done by the International Center for Research 
on Women (Nyblade et al., 2003).  The adapted scale measured perceived stigma, 
instead of experienced stigma as was the case for the original scale, because this 
seemed to be the most important influence from the qualitative findings. 
Understanding the scale properties may improve and standardize measurement of 
perceived stigma in other settings. 
5. Predictors of depression: Depression has been well documented for people living 
with HIV in North America (Berg et al., 2007; Ciesla et al., 2001; Valente, 2003), and 
emerged as prevalent in this study. The survey data can be used to identify the types 
of depressive symptoms people reported and factors associated with reporting high 
depression.  
6. Perspectives of HIV positive lay health advisors:  The interviews with VACs revealed 
that they not only perceived their contributions for improving the adherence and 
quality of life of the clinic patients, but that they also perceived benefits of the 
program for their own well-being.  The impact of lay health advisor programs on the 
lay health advisors themselves has been studied in the United States (Marino et al., 
2007), but has not been explored in Africa, where such intervention models are 
increasingly being used.     
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APPENDIX ONE 
Factors considered as determinants of poor adherence to ART in eight African studies  
 
The table below provides the factors considered as determinants of non-adherence to ART in 
eight studies (study numbers correspond to list below). Odds ratios and 95% confidence 
intervals are included for factors that were significantly associated with poor adherence at 
alpha=.05. Blank cells mean that the factor was not measured in the study and ‘n/s’ means 
that the factor was studied but found not significant. 
 
 1 2 3 4 5 6 7 
 
Demographic variables        
Age (younger) n/s 1.45 
(1.17- 
1.78) 
n/s   1.03 
(1.01- 
1.06) 
n/s 
Gender n/s  n/s  n/s n/s n/s 
Marital status (being single) 2.77 
(1.64- 
4.67) 
     n/s 
Education (higher levels) n/s  3.08 
(1.25- 
7.60) 
 n/s  3.87 
(1.21- 
12.40) 
Religion n/s       
Employment     n/s  n/s 
Income / socio-economic status (low SES) 2.93 
(1.32- 
6.50) 
n/s n/s  n/s n/s  
        
Psychological variables        
HIV optimism  1.26 
(1.01-
1.58) 
     
Outcome expectations / confidence in ART n/s       
Knowledge / beliefs about ART n/s    n/s   
Knowledge / beliefs about HIV     n/s   
Depression / negative affect n/s       
Worries about side effects     n/s   
Impact of illness on work and relationships       n/s 
Attitude toward western medicine       n/s 
Use of alcohol and drugs n/s       
        
Social variables        
Social support n/s 1.66 
(1.24-
2.24) 
     
Fear of stigmatization by a partner     8.0 
(1.4 – 
50) 
  
Disclosure of HIV status       n/s 
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Health facility and provider variables        
Vicinity of residence to the clinic n/s       
Costs of medication or reporting cost as a 
barrier 
n/s   Sig   9.09 
(3.33 – 
25.0) 
Ever received counseling   n/s     
        
Treatment-related variables        
Regimen n/s  n/s Sig n/s  n/s 
Time on ART n/s  n/s n/s   n/s 
Side effects of medication n/s      n/s 
Number of pills / doses per day (more)  1.47 
(1.14- 
1.91) 
n/s   3.07 
(1.40 – 
6.74) 
n/s 
Requirement to take pills on an empty 
stomach 
     n/s  
Use of traditional medicines       n/s 
CD4 count at initiation  1.43 
(1.10-
1.88) 
     
 
Studies reviewed: 
1. Byakika-Tusiime, J., J. H. Oyugi, et al. (2005). "Adherence to HIV antiretroviral 
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APPENDIX TWO: 
Survey questionnaire 
 
 
 
Study ID:    ____ ____ ____   Date:  ____ / ____ /    2007     
                                                                        mm     dd       YYYY   
 
Clinic ID:  ____ -  ____  - ____  Interviewer: _______________________ 
     
   
 
I. DEMOGRAPHICS 
 
1. [Mark this – do not ask] What is the 
patient’s gender 
1. Male 
2. Female 
2. What is your birth date? ___ / ___ / ________ 
mm    dd    YYYY 
If birthdate is unknown 
3. How old are you? 
1. I am ____________________ years old 
 
4. How many years of school have you 
completed?  
1. No education 
2. Less than Standard 7 
3. Completed Standard 7 only 
4. Some secondary school 
5. Completed secondary school 
6. Some post-secondary education 
 
5. What language do you speak most 
often in the home?   
1. Kiswahili 
2. Masaai 
3. English 
4.Other, specify:____________________________ 
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6. What is your religion? 1. Muslim 
2. Christian, specify: ___________________________ 
3. Other, specify: _____________________________ 
4. I have no religion  
 
7. How often do you go to church or 
mosque?   
1. Every day  
2. More than once a week 
3. Once a week 
4. In a month I go ____ times 
5. Less than once a month 
6. Never 
8. Are you currently married? 
 
1. Yes 
2. No 
9. If yes: In the past month, have you 
lived together with your spouse? 
1. Yes, we live together all the time 
2. Yes, but my spouse also lives somewhere else.  
     Reason: _____________________________ 
3. No, my spouse lives somewhere else  
     Reason: _____________________________ 
10. Is your spouse HIV positive? 1. Yes 
2. No 
3. Never tested 
11. If yes: Is your spouse taking ARVs? 1. Yes 
2. No 
12. If no: What is your relationship status? 1. Widowed 
2. Divorced 
3. In a relationship, living with partner 
4. In a relationship, not living with partner 
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5. Single, never married, no current partner 
13. If widowed: Did your spouse die of 
HIV? 
1. Yes 
2. No 
3. S/he never tested 
14. If divorced or separated:  Was the 
divorce/separation due to HIV? 
1. Yes 
2. No 
3. Don’t know 
 
15. How many children do you currently 
have? 
__________ children [If 0, go to 18] 
16. How many of these children have their 
primary residence in your home? 
__________ children  
17. How many of these children are HIV 
positive? 
__________ children 
88. Don’t know 
18. Have you had any children who have 
died? 
__________ children [If 0, go to 20] 
19. How many of those children who do 
you think died of HIV? 
__________ children 
88. Don’t know 
 
 
Does your household own: 
 Yes No 
20. Radio or music system? 1 2 
21. Television? 1 2 
22. Bicycle? 1 2 
23. Car? 1 2 
24. Telephone? 1 2 
25. Refrigerator? 1 2 
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26. Cows? 1 2 
27. Small animals, like goats and 
chickens? 
1 2 
28. A farm or a plat of land? 1 2 
Does the house where you live have: 
29. Electricity? 1 2 
30. Piped water inside the house? 1 2 
 
 
31. What kind of toilet does your 
household use? 
1. Drop toilet 
2. Flush toilet 
3. No toilet facility 
32. Do you share the toilet with any other 
households? 
1. Yes 
2. No 
33. What is your house made of? 1. Block 
2.Mud house with iron roof 
3.Mud house with grass roof 
4.Other: ____________________________ 
34. Do you own or rent your house? 1. Own 
2. Rent 
35. How many rooms does your house          
have? 
_________ rooms 
36. Including you, how many people 18 
years and older live in your house? 
_________ adults 
37. How many people under 18 years live 
in your house? 
_________ children 
38. How many meals do you usually have 
per day? 
 
_________ meals 
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39. How often in the last month did you 
have problems in satisfying the food 
needs of the household? 
1. All the time 
2. Some times  
3. A few times 
4. No times at all 
40. Have you ever received food support 
from this clinic? 
1. Yes. Number of times: _________ 
2. No 
 
41. In the past year, have you ever 
received food support from any other 
organization? 
1. Yes 
2. No 
 
42. What type of economic activities do 
you do? 1. Not working 
2. Farming 
3. Petty trading 
4. Employed with a salary 
5. Other: ______________________ 
43. Does your work require you to travel 
outside of Arusha?  
 
1. Yes 
2.  No 
44. In the past month, how much did you 
earn from your economic activities? 
 
Tsh ___________________________ 
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II. TREATMENT AND HIV-RELATED  VARIABLES 
 
1. When did you first learn your HIV 
status?  
___ / ___ / ________ 
mm    dd    YYYY 
2. When did you start taking ART? 
[If they don’t know, check their patient 
card] 
___ / ___ / ________ 
mm    dd    YYYY 
 
 
III. SOCIAL SUPPORT 
 
 
People sometimes look to others for companionship, assistance, or other types of support. I’m now 
going to ask you about how often different types of support are available to you if you need it. For 
each type of support that I mention, please tell me how often you feel that support is available to you.  
You can answer: none of the time, a little of the time, some of the time, most of the time or all of the 
time. 
 
 
 None of 
the time 
A little 
of the 
time 
Some of 
the time 
Most of 
the time 
All of the 
time 
1. Someone you can count on to listen 
to you when you need to talk 
1 2 3 4 5 
2. Someone to give you information 
to help you understand a situation 
1 2 3 4 5 
3. Someone to give you good advice 
about a crisis 
1 2 3 4 5 
4. Someone to confide in or talk to 
about yourself or your problems 
1 2 3 4 5 
5. Someone whose advice you really 
want 
1 2 3 4 5 
6. Someone to share your most 
private worries and fears with  
1 2 3 4 5 
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 None of 
the time 
A little 
of the 
time 
Some of 
the time 
Most of 
the time 
All of the 
time 
7. Someone to turn to for suggestions 
about how to deal with a personal 
problem 
1 2 3 4 5 
8. Someone who understands your 
problems 
1 2 3 4 5 
9. Someone to help you if you were 
confined to bed 
1 2 3 4 5 
10. Someone to take you to the doctor 
if you needed it 
1 2 3 4 5 
11. Someone to prepare your meals if 
you were unable to do it yourself 
1 2 3 4 5 
12. Someone to help with daily chores 
if you were sick 
1 2 3 4 5 
13. Someone to remind you to take 
your pills 
1 2 3 4 5 
14. Someone to give you spiritual help 1 2 3 4 5 
15. Someone to give you courage in 
living with HIV 
1 2 3 4 5 
16. Someone who can pick up your 
pills at the clinic if you’re not able 
1 2 3 4 5 
17. Someone to give you money if you 
don’t have it 
1 2 3 4 5 
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IV. ADHERENCE TO ART 
 
1. Which pills do you take for your HIV? 
 
1. Triomune 30 
2. Triomune 40 
3. Combivir / EFV 
4. Other: __________________ 
 
2. What time do you generally take your 
morning dose? 
 
Time: _________________ 
3. What time do you generally take your 
evening dose? 
 
Time: _________________ 
 
We understand that it is common that people forget to take their pills or have reasons for deciding not 
to take their pills. That’s normal. I’m going to ask you some questions about YOUR experiences 
taking ARVs. Remember what you say to me will not be shared with anyone 
and I personally don't care what your answer is.  
For each day, first ask a question to get them thinking about the day (What did you do yesterday?). 
Then ask about whether they took a pill in the morning and in the evening and at what time. Record 
the time taken in the box below. If the patient reports not taking a dose, put an X in the cell. 
4. Please circle: What day of the week is TODAY? 
1)Monday    2)Tuesday    3)Wednesday    4)Thursday    5)Friday    6)Saturday     7)Sunday     
 
FOR CODER: 1)Took dose on time, 2)Took dose 1 hr. or more earlier than usual, 3)Took dose 1 hr. 
or more later than usual, 4) Took dose but not sure of time, 5) Not sure if s/he took dose, 6)Didn’t 
take dose, 7) Time for dose has not arrived 
 
 
Previous four days 
[Write the appropriate days of the week on the lines below] 
5. _____ 
Today 
6. ______ 
Yesterday 
7. ______ 
2 days ago 
8. ______ 
3 days ago 
9. ______ 
4 days ago 
a.  
Morning 
dose 
     
b. 
Evening 
dose 
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For each missed dose or dose taken at least one hour later than the time they say they normally take 
their pills, ask the question: 
 
Take out the container of beads. 
 
Now I want you to think about the past month and how many of your prescribed ARV pills you have 
taken.  In this jar is 60 beads.  This represents all the pills you should have taken in the past month. 
We know that not all patients take all their pills for different reasons.  I want you to show me how 
many of these pills you took by putting into this other container the number of these pills you think 
you actually took in the past month.  
 
14. Record the number of beads in the original 
jar. 
 
Number of beads: _____________ 
15. If there are any beads in the original jar: 
What were your reasons for not taking these 
pills? 
 
 
 
 
 
 
 
 
 
10. MISSED DOSE 1: What was your reason for 
not taking that dose / taking it late? 
 
 
 
 
 
 
11. MISSED DOSE 2:  What was your reason for 
not taking that dose / taking it late? 
 
 
 
 
 
 
12. MISSED DOSE 3:  What was your reason for 
not taking that dose / taking it late? 
 
 
 
 
 
 
13. MISSED DOSE 4:  What was your reason for 
not taking that dose / taking it late? 
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V. BELIEFS ABOUT ARVs 
Now I'm going to read you some things people believe about HIV and ARVs. Please tell me how you 
feel about each one. 
 
1. Do you think antiretrovirals can: totally remove HIV 
from your body, improve your health but not remove 
HIV from your body, or do they not help much at all? 
1. Totally remove HIV from your body 
2. Improve your health but not remove 
HIV from your body 
3. They do not help much at all 
2. Once people start feeling better, should they: stop 
taking antiretrovirals immediately, keep taking them 
for a while longer and then stop, or keep taking them 
for the rest of their lives? 
1. Stop taking ARVs immediately 
2. Keep taking them for a while longer to 
make sure the symptoms have really 
stopped, and then stop taking them 
3. Keep taking them for the rest of their 
lives 
3. When should you take your ARVs: only when you’re 
feeling sick, only when you’re feeling healthy, or all 
the time, no matter if you feel sick or healthy? 
1. Only when you’re feeling sick 
2. Only when you’re feeling healthy 
3. All the time, no matter if you feel sick 
or healthy 
4. Do people who are on antiretrovirals need to use 
condoms when they have sex or are those people no 
longer able to spread HIV so they don’t need 
condoms? 
1. Need to use condoms 
2. Those people are no longer able to 
spread HIV so don’t need to use 
condoms 
 
5. If a man and a woman are both HIV positive and 
taking ARVs, should they: stop having sex altogether; 
reduce the frequency of having sex; or continue 
having sex as often as before? 
1. Stop having sex altogether 
2. Reduce the frequency of having sex 
3. Continue having sex as before 
6. When should people take their ARVs: at the same 
time every morning and evening; anytime, as long 
they take it in the morning and evening; or it doesn't 
matter as long as they take two pills per day? 
1. At the same time every morning and 
evening 
2. Anytime, as long as they take it in the 
morning and evening 
3. It doesn't matter when as long as they 
take two pills per day 
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7. If someone in your family is sick with HIV, is it okay 
to share you antiretrovirals with that person or should 
you make sure you never give your  ARVs to 
someone else to take? 
1. It’s okay to share your ARVs 
2. You should never give your ARVs to 
anyone else 
 
8. When you take antiretrovirals, does the amount of 
body immunity / CD4 increase, decrease or stay the 
same? 
1. Increase 
2. Decrease 
3. Stay the same 
9. When you take antiretrovirals, does the amount of 
virus in your body increase, decrease or stay the 
same? 
1. Increase 
2. Decrease 
3. Stay the same 
 
 
 
 
  
 
VI. HIV DISCLOSURE EXPERIENCES 
 
Now I want to talk to you about whether or not you have ever talked to different people about your HIV status and about the fact that you are 
taking medication for HIV. Different people do different things when they learn they are HIV-positive. Some people tell their friends, families 
and sexual partners, others don’t tell anyone. Please remember that I will not tell anyone what you tell me in this interview. 
 
 
a. Have you talked to this 
person about the fact that 
you’re HIV-positive? 
b. After you told this person 
you were HIV+, would you 
say that their response was 
positive, negative or neutral? 
c. If haven’t 
disclosed directly: 
Do you think this 
person knows that 
you’re HIV 
positive, even if you 
didn’t tell them 
directly? 
d. Does the person 
know that you are 
taking ARVs? 
e. Does this person 
give you any help in 
remembering to take 
your ARVs? 
f. If yes: Would you say 
he/she gives you: a little 
support or a lot of support to 
help you remember to take 
your ARVs? 
 Yes No N/A Pos Neg Neut. Yes No Yes No Yes No A little A lot 
1. Spouse or 
partner 
1 2 3 1 2 3 1 2 1 2 1 2 1 2 
2. Mother 1 2 3 1 2 3 1 2 1 2 1 2 1 2 
3. Father 1 2 3 1 2 3 1 2 1 2 1 2 1 2 
4. Any blood 
brothers 
1 2 3 1 2 3 1 2 1 2 1 2 1 2 
5. Any other 
brothers 
1 2 3 1 2 3 1 2 1 2 1 2 1 2 
6. Any blood 
sisters 
1 2 3 1 2 3 1 2 1 2 1 2 1 2 
7. Any other 
sisters 
1 2 3 1 2 3 1 2 1 2 1 2 1 2 
8. Any brothers- 
or sisters-in-
law 
1 2 3 1 2 3 1 2 1 2 1 2 1 2 
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9. Any uncles  1 2 3 1 2 3 1 2 1 2 1 2 1 2 
10. Any aunts 1 2 3 1 2 3 1 2 1 2 1 2 1 2 
11. Any children 
over age 15 
1 2 3 1 2 3 1 2 1 2 1 2 1 2 
12. Any friends 1 2 3 1 2 3 1 2 1 2 1 2 1 2 
13. Any neighbors 1 2 3 1 2 3 1 2 1 2 1 2 1 2 
14. A pastor or 
other religious 
leader 
1 2 3 1 2 3 1 2 1 2 1 2 1 2 
15. Any 
workmates 
1 2 3 1 2 3 1 2 1 2 1 2 1 2 
16. The person 
who owns your 
house 
1 2 3 1 2 3 1 2 1 2 1 2 1 2 
17. Your house 
boy/girl 
1 2 3 1 2 3 1 2 1 2 1 2 1 2 
18. Who did you tell about your status first, second and third? 1. _______________________________ 
2. _______________________________ 
3. _______________________________ 
19. How many people outside this clinic have you told about your status?  _____________ people 
[If respondent says they’ve disclosed to ‘all or ‘many’, confirm 
that it is more than 5 and write ‘>5’ on line above] 
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VII. PERCEIVED STIGMA 
 
There are a lot of social and emotional aspects of having HIV. Some people have bad experiences 
because of having HIV, or are afraid that people will react badly because they have HIV.  I’m going 
to ask you how afraid you are of certain things happening if people knew your HIV status. I want you 
to respond by telling me whether you are: not afraid at all, just a little afraid, somewhat afraid, or very 
afraid. 
 Not 
worried 
at all 
Just a 
little 
worried 
Some-
what 
worried 
Very 
worried 
1. How worried or not worried are you that you would be 
treated differently / shunned at a social gathering if 
people knew your HIV status? Are you: 
1 2 3 4 
2. How worried or not worried are you that you would be 
abandoned by your family / sent away to the village if 
people knew your HIV status? Are you: 
1 2 3 4 
3. How worried or not worried are you that you would be 
isolated in your household (made to eat along / made 
to use separate eating utensils / made to sleep alone in 
your room) if people knew your HIV status? Are you: 
1 2 3 4 
4. How worried or not worried are you that you would no 
longer be visited or would be visited less by family 
and friends if people knew your HIV status? Are you: 
1 2 3 4 
5. How worried or not worried are you that you would be 
teased, insulted or sworn at if people knew your HIV 
status? Are you: 
1 2 3 4 
6. How worried or not worried are you that you would 
lose customers to buy your produce / goods or lose a 
job if people knew your HIV status? Are you: 
1 2 3 4 
7. How worried or not worried are you that you would 
lose housing or not be able to rent housing if people 
knew your HIV status? Are you: 
1 2 3 4 
8. How worried or not worried are you that you would be 
denied religious rites/services (marriage, communion, 
burial, singing in the choir, prayer) or not be allowed 
to go to church or mosque if people knew your HIV 
status? Are you: 
1 2 3 4 
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9. How worried or not worried are you that you would 
lose respect / standing within the family or community 
if people knew your HIV status? Are you: 
1 2 3 4 
10. How worried or not worried are you that you would be 
gossiped about if people knew your HIV status? Are 
you: 
1 2 3 4 
 
 
VIII. DEPRESSION 
 
Sometimes people lose hope or courage when they have different problems in day-to-day life. I’m 
going to ask you how often you felt different ways in the past month. 
 
 Never Seldom Some of 
the time 
Very 
often 
1. Felt hopeless about the future 1 2 3 4 
2. Felt worthless  1 2 3 4 
3. Felt blue 1 2 3 4 
4. Thought of ending your life 1 2 3 4 
5. Felt trapped or caught 1 2 3 4 
6. Blamed yourself for things 1 2 3 4 
7. Felt lonely 1 2 3 4 
8. Worried too much about things 1 2 3 4 
9. Cried easily 1 2 3 4 
10. Felt everything is your fault 1 2 3 4 
11. Not felt interested in things 1 2 3 4 
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IX. PERCEIVED SELF-EFFICACY TO ADHERE 
 
There are a lot of situations that people talk about that make it difficult for people who are HIV positive 
to take their pills every day and on time. Now I want to ask you about some of those situations. I’d like 
you to tell me how confident or not confident you are that you can take your pills correctly if you were in 
these different situations. 
 
 Amount of confidence 
 
 
Almost no 
confidence
A little 
confidence
Some 
confidence 
A lot of 
confidence 
1. If you have side effects from taking ARV, 
how much confidence do you have that you 
will be able to take your ARV medications? 
Do you have: 
 
1 2 3 4 
2. If you travel away from home, how much 
confidence do you have that you will be able 
to take your ARV medications? Do you have: 
1 2 3 4 
3. If you are very busy with work, how much 
confidence do you have that you will be able 
to take your ARV medications? Do you have: 
1 2 3 4 
4. If you are busy participating in community 
events, such as funerals, weddings, how much 
confidence do you have that you will be able 
to take your ARV medications? Do you have: 
1 2 3 4 
5. If you are busy with activities in the church or 
mosque, how much confidence do you have 
that you will be able to take your ARV 
medications? Do you have: 
1 2 3 4 
6. If you become sick, how much confidence do 
you have that you will be able to take your 
ARV medications? Do you have: 
1 2 3 4 
7. If you are feeling very tired, how much 
confidence do you have that you will be able 
to take your ARV medications? Do you have: 
1 2 3 4 
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 Amount of confidence 
 
 
Almost no 
confidence
A little 
confidence
Some 
confidence 
A lot of 
confidence 
8. If you are with someone when you have to 
take your medications who doesn’t know that 
you HIV+, how much confidence do you have 
that you will be able to take your ARV 
medications? Do you have: 
1 2 3 4 
9. In the situation when you don’t have food, 
how much confidence do you have that you 
will be able to take your ARV medications? 
Do you have: 
1 2 3 4 
10. In the situation where you health has 
improved greatly, how much confidence do 
you have that you will be able to take your 
ARV medications? Do you have: 
1 2 3 4 
 
 
X. NORMATIVE BELIEFS 
 
1. Has anyone ever told you that taking ARVs makes 
you die sooner? 
1. Yes, Who: ________________ 
2. No [Go to 3] 
 
2. Do you value the opinion of the person who told you 
that: a lot, a little, or not much at all? 
1. A lot 
2. A little 
3. Not much at all 
3. Has anyone ever said to you that you should take 
traditional medicines instead of taking ARVs?  
1. Yes, Who: _________________ 
2. No [Go to 5] 
 
4. Do you value the opinion of the person who told you 
that: a lot, a little, or not much at all? 
1. A lot 
2. A little 
3. Not much at all  
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5. Has anyone ever told you that you should pray instead 
of taking ARVs?  
1. Yes, Who: _________________ 
2. No [Go to next section] 
 
6. Do you value the opinion of the person who told you 
that: a lot, a little, or not much at all? 
1. A lot 
2. A little 
3. Not much at all  
 
 
 
XI. SKILLS AND STRATEGIES APPLIED FOR TAKING MEDICATION 
 
Some people do things so that they are better able to remember to take their ARV medications every 
day, on time. I’m going to tell you about some different strategies people have used to remember to 
take their pills, and I want you to tell me whether you have ever done this in the past month.  
 
In the last month … 
 
 Yes No 
1. …have you carried your pills in your pocket 
or handbag if you leave home? 
1 2 
2. ...have you timed taking your pills so that it 
corresponds to another event, like having a 
bath, brushing your teeth, or saying your 
prayers? 
1 2 
3. …have you placed your pills in an open 
space so that you remember to take them? 
1 2 
4. …have you set an alarm to remember to take 
your pills? 
1 2 
5. …have you used a radio or TV program to 
remind you that it’s time to take your pill? 
1 2 
6. …have you had someone remind you to take 
your pills? 
1 2 
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XII. PERCEIVED SIDE EFFECTS 
 
1. In the last month, have you 
experienced any side effects related to 
the ARVs? 
1. Yes 
2. No 
2. If yes: Please describe those side 
effects. 
 
 
 
 
 
 
 
 
 
 
XIII. PATIENT-PROVIDER COMMUNICATION 
 
I am going to ask you some questions about is your relationship with the hospital staff, namely with 
the doctors, nurses, counselors and pharmacists. Remember, your answers are confidential and we 
will not share what you say with the clinic staff. 
When you come into the clinic to receive care, how often do you feel that… 
 
 Never Sometimes Usually Always 
1. …the hospital staff give you enough 
time every time you come to the clinic? 
Do you feel that way: 
1 2 3 4 
2. …the hospital staff are willing to listen 
to you problems or to your concerns? Do 
you feel that way: 
1 2 3 4 
3. ..the hospital staff help you to find 
solutions to problems related to your 
health? 
1 2 3 4 
4. …the hospital staff are able to explain 
things to you in a way that you can 
understand? Do you feel that way: 
1 2 3 4 
5. … you are able to contact or meet the 
hospital staff whenever you need to? Do 
you feel that way: 
1 2 3 4 
  128
 Never Sometimes Usually Always 
6. …you are comfortable talking openly 
with the care providers at the hospital? 
Do you feel that way: 
1 2 3 4 
7. …you get good care for your conditions 
from the hospital staff? Do you feel that 
way: 
1 2 3 4 
8. …the hospital staff help-provide advice 
to you for any problems you have in 
taking your medications? Do you feel 
that way: 
1 2 3 4 
9. …the hospital staff understand the 
difficulties that you face taking your 
ARV medications? Do you feel that 
way: 
1 2 3 4 
10. …the hospital staff advise you how to 
reduce side affects from your ARV 
medications? Do you feel that way: 
1 2 3 4 
11. …the hospital staff encourage you to 
take your ARV medications? Do you 
feel that way: 
1 2 3 4 
 
XIV. VOLUNTARY ADHERENCE COUNSELORS 
 
1. The VACs are the people who come on 
clinic days and are supposed to help 
patients take their pills. Do you have a 
VAC? 
1. Yes 
2.  No 
3. Don’t know 
2. If yes: Who is your VAC? Name: __________________________ 
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3. When you come to the clinic, how 
often do you talk to your VAC? 
1. Never 
2. Sometimes 
3. Usually 
4. Always 
4. Has this person ever visited you at 
home? 
1. Yes 
2.  No 
 
5. Do you belong to any organizations for 
people living with HIV? 
1. Yes 
2. No 
 
 
XV. ACCESSIBILITY TO THE CLINIC 
 
1. How many minutes does it usually take 
you to get from your house to this 
clinic? 
1. ________ minutes 
 
2. What form of transportation do you 
usually use to get from your house to 
the clinic? 
1. Walk 
2. Personal car 
3. Car of relative or friend, Cost each way: 
________ 
3. Hired taxi, Cost each way: ________ 
4. Daladala, Cost each way: __________ 
5. Bicycle 
 
3. Since you started taking ARVs, how 
often have you missed an appointment 
at the clinic for the time to pick up 
your ARVs? 
 
1. Never 
2. Once  
3. 2-3 times 
4. More than 3 times 
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4. What were your reasons for missing 
the appointments? (Circle all that 
apply) 
1. Travelling outside of Arusha 
2. No transportation fare 
3. Unable to come due to weather  
4. Forgot 
5. Sick 
6. Other reasons:__________________ 
 
 
 
These are all the questions I have for you. Is there anything you would like to add about your 
experiences living HIV or taking antiretroviral medications? 
 
 
 
 
 
 
 
 
 
Do you have any questions for me? 
 
 
 
 
 
 
 
 
  
 
THANK YOU for taking the time to be part of this study. The information you provided will help to 
improve services for people living with HIV. 
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APPENDIX THREE: 
In-depth interview guide for ART patients 
 
 
I.  INTRODUCTION/PERSONAL INFORMATION 
 
To begin, I want to know a little about yourself.  
 
1) Where were you born? In what year? [If they don’t know the year, how old are you?] 
 
2) How much school did you complete? 
 
3) Your religion? How is your involvement in this religion? (frequency, etc) 
 
4) What types of economic activities are you involved in? Has it changed since being 
HIV positive? Do you get enough money to support yourself? 
 
5) Where do you live now? 
 
6) How much time does it usually take you to get from where you live to the clinic? 
How do you usually travel here? Do you ever find problems in coming to the 
coming? 
 
7) Who do you live with at your home? 
 
8) Are you currently married? [Probe: relationship status] 
 
9) Do you have children? How many? Ages? 
 
 
HIV in the family 
 
Now I would like to talk with you about HIV/AIDS in your life and your family. 
 
1) Is anyone else in your family HIV-positive? [probe for spouse] 
 
2) Has anyone in your family died of AIDS? 
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II. EXPERIENCE BEING DIAGNOSED WITH HIV 
 
I would like to know how you found out you were HIV positive, and what you have done 
since then. 
 
1) Please tell me about the events that led you to get tested for HIV [ Probe: Motivation 
for being tested, illness, where tested, who went with them to get a test] 
 
2) When did you learn that you were HIV- positive? [Probe: Month and year] 
 
3) How was it for you after you learned your HIV status? [Probe: First month, feelings, 
reactions, intentions and decisions] 
 
4) When you went for the HIV test, did you know about these drugs (ARVs)? What did 
you know about them? 
 
5) How do you think you became infected? 
 
6) Apart from going to the clinic, many people try to find other ways to get relief from 
HIV. For example they go to traditional healers and herbalists. How about you?  
 
 
III. EXPERIENCE TAKING ARVS 
 
I am interested in learning about your experiences taking medication for your HIV. 
 
1)  [Show him/her antiretroviral medications]  Which of these medicines do you take?  
 
2) When did you start taking ARVs?[ Probe: Month and year] 
 
3) Please tell me the events that led you to start taking these drugs. [ Probe how did you 
find out about them, what did you know about them, who or what persuaded you to 
look for medication] 
 
4) How has taking ARVs changed your life? [Probe for both positive and negative 
changes] 
 
5) How do you think these drugs work in your body? 
• Do they cure you? Why not? 
• What will happen if you stop taking them?  
• What will happen if you don’t take them every day? 
 
6) You know, when you come to the clinic, they often mesaure your CD4. Do you know 
what this CD4 indicates?
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IV.  ADHERENCE  
 
I would like to understand how taking ARVs fits into your daily life 
 
1) Tell me about your normal timetable, from the time you get up in the morning to the 
time you go to sleep at night, and taking ARVs fits into this? [Probe: time when they 
eat and when they take ARVs] 
• How many meals do you get per day? 
• Are there other days that have different time schedules? [Probe: how 
this affects taking ARVs] 
 
2) What things do you do so that you are able to take your antiretrovirals on time? 
[Probe for strategies to help them remember their pills] 
 
3) Some people have times when it is hard for them to take their ARVs when they are 
supposed to. In what circumstances do you find it hard to take your pills? [Probe: 
Side effects, remembering, traveling, hiding the drugs, running out of pills, not 
having food] 
 
4) Do you travel? Is it hard to take your ARVs when you travel or just the same when 
you are at home? Then: Tell me your experiences taking ARVs when you are 
traveling. 
 
5) Please think about the last time you missed taking your ARVs. Tell me about that 
time. 
 
6) In the last month about how often do you think you missed taking your antiretroviral 
medications. [Probe for reasons] 
 
V. RELIGION 
 
I would like to understand the role of religion in your life and how it helps you in using 
ARVs. 
 
1) Since you learned that you were infected, how was your involvement (in religion) 
changed? 
 
2) What kind of support do you get from the church / mosque? 
 
3) Do people at your church / mosque know that you’re HIV positive? (probe: pastor, 
imam)  
 
4) What do you hear them say about AIDS? ARVs? 
 
5) Have you heard of anyone being cured of HIV because of prayer? 
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VI. DISCLOSURE, SOCIAL SUPPORT AND STIGMA 
 
Now I would like to know a little about who in your life knows that you are HIV-positive, 
other than people at this clinic. 
 
1) Who is the first person you told about your HIV status? When? Why? What was the 
reaction? 
 
2) Who is the second person you told about your HIV status? When? Why? What was 
the reaction? 
 
3) Who is the third person you told about your HIV status? When? Why? What was the 
reaction? 
 
4) Who else knows apart from these three? 
 
5) [If more than 3 mentioned] Of these people, which three are most important to you? 
 
For each person mentioned [up to three]: 
 
1) How has your relationship with this person changed since telling them about your 
HIV status? 
 
2) Has this person given you help in dealing with your HIV status? If yes, Tell me how 
this person has helped you deal with your HIV status. [Probe for examples] 
 
3) Does this person know you are taking ARVs? [If no, probe for reasons] 
 
4) Has this person given you help in taking ARVs? If yes: Please tell me how this person 
has helped take ARVs [Probe for examples] 
 
Social support 
 
1) Which of these people you have told me about has provided the most help to you 
since you have started taking ARVs? Why do you say this? 
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Disclosure 
 
1) Is there any one who does not know that you are HIV positive? (Probe: Family, 
friends, neighbors, workplace) 
 
If someone in the household does not know they are HIV-positive:  
 
• What made you decide not to tell this person your HIV status?  
• What do you think would happen if this person knew? 
 
Stigma 
 
There are things we’ve heard from the radio that some people are discrimated against 
because they are HIV positive. 
 
1) Have you ever heard anyone else being treated differently because they are HIV 
positive? Tell me about that. 
 
2) Has any one ever treated you differently because you are HIV positive? Tell me about 
that.  
 
 
VII. RELATIONSHIP WITH SERVICE PROVIDERS 
 
 
Support from VACs 
 
Now I would like to know about your relationship with VACs who work at this clinic. 
 
1) Do you know who these VACs are? 
 
2) Do you have a VAC? Who? 
 
3) Where do you meet? Clinic? Home? When? How often? 
 
4) What kind of things do you talk about with [VAC]? 
 
5) What kind of help do you get from your VAC? 
 
6) What other things would you like your VAC to help you with? 
 
Support from the clinic 
 
1) Is there anything else that this clinic can do to better support you, and other people 
like you, in taking ARVs? 
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VIII. CONCLUSION 
 
Now I have asked you all my questions.  
 
1) Do you have anything else you would like to tell me about  your experiences as a 
person living with HIV or your experiences taking ARVs? 
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APPENDIX FOUR: 
In-depth interview guide for health care providers` 
 
 
1. INTRODUCTION / PERSONAL INFORMATION / HISOTRY 
 
Can you please tell me a little about yourself. 
 
• Where are you from? 
 
• How old are you? 
 
• What is your level of education? 
 
• Who do you live with at your home? 
 
 
[Verify position /work in the clinic] 
 
Can you explain to me how you became a nurse/doctor/councellor/ pharmasist, and how 
come you are a worker in this clinic? 
 
• What motivated /attracted you to become a health worker? 
 
 
2. RELATIONSHIP WITH ART PATIENTS AND THE SYSTEM OF 
ASSISTING THEM 
 
I would like to know what type of work you do in this clinic. Could you please explain your 
daily activities. What do you normaly do from morning to evening until when you finsh 
/complete your work. 
 
• What type of service did you offer? 
 
• How many patients did you attend? 
 
• How long did you take to attend each patient? 
 
• Generally what part of your work do you enjoy most. 
 
• What challenges do you face in your work? 
 
• How do other working days differ from this particular day? 
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Explain to me your experience of caring for patients who use ARVs. 
 
• What kind of service and assistance do you give to patients who use ARVs? 
 
• What type of conversation do you have with patients who use ARVs. Give examples 
 
• Do patients who use ARVs tell you what kind of problems they have? Give examples. 
How do you assist them(Give examples) 
 
 
What are your experiences working with friends, partner or family members who come to the 
clinic with ART patients? 
 
• Who do patients bring with them to the clinic? (Differentiate by patients’ gender 
and age) 
 
• How often do you meet with them? 
 
• What kind of conversation do you normally have with them? Tell me about the 
problems they talk to you about and solutions you offer them. (Give examples) 
 
• What are the benefits of  patients coming to the clinic with their 
helpers/assistants? (Differentiate by gender/age) 
 
• How do patients who come to the clinic with helpers differ from those who come 
without helpers? 
 
• Beside family members/relatives who else usually assist the patients who use 
ARVs?  
 
 
Please tell me the changes you have noticed from  people since they started using ARVs. 
 
• What are the positive or negative changes? 
 
• Do these changes differ for women and men? 
 
• What are the differences between young and old people? 
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3. PERSPECTIVE OF THE WAYS PEOPLE MANAGE ADHERENCE 
 
Tell me the challenges/problems which patients can face by using medicine daily and in the 
period they are supposed to use them. 
 
For each problem/challenge mentioned, enquire for more examples about the type of advice 
they gave. 
 
 
• In what environment/situation is it difficult for patients to follow their medicine 
regulations? Examples. 
  
• In these situations, what type of advice do you give them? Examples. 
 
• What types of patients get more problems using ARVs? 
 
• How do family members/relatives help patients to use of medicine? Example. 
 
• Are there patients who do not have help from family or friends? What do  they 
do? Examples. 
 
• What things do people do to remeber to take their medications as they are 
supposed to? Examples. 
 
• When do the patients get more problems using the medicine? When they just start, 
or after they have used for a long time? Why do you think so? 
 
• Do you know patients who reject using their medications? (Example, reasons) 
 
• Are there patients who have stopped using the drugs completely? (Example, 
reasons) 
 
• Patients of which gender have the most problems taking ARVs, males or females? 
What about old and young peopel? Why do you think so? Examples. 
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Think about a patient you take care of who has a lot of problems taking their medications 
every day as they should. Tell me about this person.  
 
What about a person who you take care of who is good in taking medications every day as 
they should. How is that person? 
 
• Is it a man or a woman? 
 
• How old is the patient? 
 
• What is the person’s living situation? Married? Children? 
 
• Who knows that the person is living with HIV and is taking medication? 
 
• What kinds of help does the person get from others? From which people does the person 
get help? 
 
• In which situations does the person get difficulties adhering to the medications? 
 
• What strategies does the person use to take the medications? 
 
• How has the person’s adherence changed over different time periods? 
 
• How is the person’s state of mind / mental health?  
 
• How do you support the person to take his/her medicines? 
 
 
 
Are there other things we have not yet talked about which can help me to understand how 
you help patients to take their drugs every day and on time? 
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4. CONCLUSION / THEIR EXPECTATIONS FOR PROGRESS AT WORK 
 
 
Finally, think about your work as a doctor/ nurse / counselor / pharmacist. What types of 
changes do you see in your work five years from now? Whether or not you remain working 
in this clinic. 
 
 
• What kinds of training will help you to give care in this position? 
 
• What types of career aspiritations do you have? 
 
 
What what about this clinic? What types of changes do you see in five years from now? 
 
 
• Which other types of care will be importatnt to provide to patients in this clinic? 
 
• What types of extra training will people in this clinic need? 
 
• Are there any challenges you see facing this clinic? 
 
 
Do you have any questions? 
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